13,072 results on '"Zhong, J."'
Search Results
52. Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection
- Author
-
Liu Y, He S, Yin S, Zhong Q, Zhong J, Zhang X, Fan R, and Hou J
- Subjects
hepatitis b e antigen ,hepatitis b e antibody ,Medicine (General) ,R5-920 - Abstract
Yuanyuan Liu,1,2 Songmei He,2 Sichun Yin,2 Qingyang Zhong,2 Jianbo Zhong,2 Xiaoyong Zhang,1 Rong Fan,1 Jinlin Hou1,3 1Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; 2Department of Infectious Diseases, Dongguan People’s Hospital, Dongguan, Guangdong, People’s Republic of China; 3Hepatology Unit, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Jinlin HouDepartment of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of ChinaTel +86 20 61641941Fax +86 20 62786530Email jlhousmu@163.comObjective: The detection of dual-positivity for both hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe) is not typically performed for patients with hepatitis B virus (HBV). This cross-sectional study was designed to figure out the prevalence of dual-positivity for both HBeAg and anti-HBe (DEP) among hospitalized patients with chronic hepatitis B virus infection (C-HBVI).Patients and Methods: Data from 2820 cases with C-HBVI from two centers in China were retrospectively analyzed. Univariate and multivariate logistic regression analyses were undertaken to identify the risk factors for liver fibrosis (LF) and acute-on-chronic liver failure (ACLF).Results: There were 165 (5.9%), 688, and 1903 patients in DEP, HBeAg+/anti-HBe-, and HBeAg-/anti-HBe+ groups, respectively. The DEP patients’ median age was 43.6 years old and 71.5% of them were male. They had higher levels of alanine transaminase, total bilirubin, and international normalized ratio. Furthermore, DEP cases had a higher proportion of liver cirrhosis, and it was associated with non-invasive testing of LF, including aspartate transaminase (AST)-to-platelet ratio index (APRI) > 1.5 (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.27– 3.03, P = 0.002) and fibrosis-4 (FIB-4) score > 1.45 (OR = 2.07, 95% CI: 1.28– 3.34, P = 0.003). DEP also contributed to the elevated risk of ACLF (OR = 4.80, 95% CI: 2.02– 11.39, P < 0.001).Conclusion: DEP cases are at higher risks of LF and ACLF than other patients with HBV infection. A fast diagnosis and an active monitoring of liver diseases for DEP patients are extremely vital.Keywords: hepatitis B e antigen, hepatitis B e antibody
- Published
- 2021
53. Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
- Author
-
Zhong J, Ding J, Deng L, Xiang Y, Liu D, Zhang Y, Chen X, and Yang Q
- Subjects
epcam ,aptamer ,cell-selex ,prostate cancer ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Jinman Zhong,1,* Jianke Ding,2,* Lei Deng,1 Ying Xiang,1 Duoduo Liu,1 Yanyan Zhang,1 Xin Chen,1 Quanxin Yang1 1Department of Radiology, The Second Affiliated Hospital, Xi’ an Jiaotong University, Xi’an, Shaanxi Province, 710004, People’s Republic of China; 2Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi Province, 710032, People’s Republic of China*These authors contributed equally to this workCorrespondence: Quanxin Yang; Xin ChenDepartment of Radiology, The Second Affiliated Hospital, Xi’ an Jiaotong University, 157 Xiwu Road, Xi’an, Shaanxi Province, 710004, People’s Republic of ChinaEmail quanxin1962@163.com; chen_x129@163.comBackground: The sensitive and specific detection of pathogenic cells is important in tumor diagnosis at an early stage. Aptamers are short single-stranded oligonucleotides evolved from systematic evolution of ligands by exponential enrichment (SELEX). It has been proved that aptamers can interact with cognate target molecules with high affinity and specificity and have great potential in the development of medical imaging at molecular level.Purpose: To select epithelial cell adhesion molecule (EpCAM) specific aptamers targeting prostate cancer and further to conjugate aptamers with GoldMag nanoparticles (a typical iron oxide core/gold shell structure) to construct magnetic molecular probes for medical imaging.Methods: EpCAM-specific aptamers were selected by Cell-SELEX. The enrichment of specific aptamer candidates was monitored by flow cytometric analysis. Aptamers were further conjugated with GoldMag nanoparticles to construct magnetic molecular probes. The affinity and specificity of aptamer candidates and aptamer-conjugated GoldMag nanoparticles were evaluated. The MR imaging of aptamer-conjugated GoldMag nanoparticles to prostate cancer was further explored in vitro and in vivo.Results: After 12 rounds of selection, aptamer candidates Eppc6 and Eppc14 could specifically target three types of prostate cancer cells, revealing a high affinity of Eppc6 and Eppc14. Moreover, aptamer-conjugated GoldMag nanoparticles not only exhibited good affinity to different prostate cancer cells but also produced strong T2WI signal intensity reduction distinguished from peritumoral tissue in MRI, indicating that the molecular probes possess both the affinity properties of EpCAM-specific aptamer and the superparamagnetic features of iron oxide.Conclusion: Our study indicates that aptamer Eppc6 and Eppc14 can recognize prostate cancer cells and tissues. The aptamer-conjugated GoldMag nanoparticles constructed in the study can be used as a molecular imaging agent for detection of PCa in MRI.Keywords: EpCAM, aptamer, Cell-SELEX, prostate cancer
- Published
- 2021
54. Clinical Characteristics and Outcomes of Hypertensive Patients Infected with COVID-19: A Retrospective Study
- Author
-
Chen L, Chen J, Wu Y, Zhong J, Zhou F, Liu Y, Xu A, Li J, and Cai H
- Subjects
covid-19 ,coronavirus disease ,hypertension ,clinical characteristics ,comorbidities ,Medicine (General) ,R5-920 - Abstract
Liqin Chen,1,* Jiankun Chen,1,2,* Yuwan Wu,1 Jinyao Zhong,1 Fuzhen Zhou,1 Yuntao Liu,1,2 Aiting Xu,3 Jiqiang Li,1,2 Huayang Cai1 1The Second Affiliated Hospital (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, People’s Republic of China; 2Guangzhou Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Emerging Infectious Diseases, Guangzhou, 510006, Guangdong, People’s Republic of China; 3The People’s Hospital of Yangjiang, Yangjiang, 529500, Guangdong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiqiang Li; Huayang Cai Email lijiqiangjizhen@163.com ; caihuayang@gzucm.edu.cnBackground: Hypertension has been reported as the most prevalent comorbidity in patients with coronavirus disease 2019 (COVID-19). This retrospective study aims to compare the clinical characteristics and outcomes in COVID-19 patients with or without hypertension.Methods: A total of 944 hospitalized patients with laboratory-confirmed COVID-19 were included from January to March 2020. Information from the medical record, including clinical features, radiographic and laboratory results, complications, treatments, and clinical outcomes, were extracted for the analysis.Results: A total of 311 (32.94%) patients had comorbidity with hypertension. In COVID-19 patients with hypertension, the coexistence of type 2 diabetes (56.06% vs 43.94%), coronary heart disease (65.71% vs 34.29%), poststroke syndrome (68.75% vs 31.25%) and chronic kidney diseases (77.78% vs 22.22%) was significantly higher, while the coexistence of hepatitis B infection (13.04% vs 86.96%) was significantly lower than in COVID-19 patients without hypertension. Computed tomography (CT) chest scans show that COVID-19 patients with hypertension have higher rates of pleural effusion than those without hypertension (56.60% vs 43.40%). In addition, the levels of blood glucose [5.80 (IQR, 5.05– 7.50) vs 5.39 (IQR, 4.81– 6.60)], erythrocyte sedimentation rate (ESR) [28 (IQR, 17.1– 55.6) vs 21.8 (IQR, 11.5– 44.1), P=0.008], C-reactive protein (CRP) [17.92 (IQR, 3.11– 46.6) vs 3.15 (IQR, 3.11– 23.4), P=0.013] and serum amyloid A (SAA) [99.28 (IQR, 8.85– 300) vs 15.97 (IQR, 5.97– 236.1), P=0.005] in COVID-19 patients with hypertension were significantly higher than in patients without hypertension.Conclusion: It is common for patients with COVID-19 to have the coexistence of hypertension, type 2 diabetes, coronary heart disease and so on, which may exacerbate the severity of COVID-19. Therefore, optimal management of hypertension and other comorbidities is essential for better clinical outcomes.Keywords: COVID-19, coronavirus disease, hypertension, clinical characteristics, comorbidities
- Published
- 2021
55. Relationship Between Skeletal Muscle Mass to Visceral Fat Area Ratio and Cardiovascular Risk in Type 2 Diabetes
- Author
-
Liu D, Zhong J, Wen W, Ruan Y, Zhang Z, Sun J, and Chen H
- Subjects
type 2 diabetes mellitus ,cardiovascular diseases ,skeletal muscle mass to visceral fat area ratio ,risk assessment ,Specialties of internal medicine ,RC581-951 - Abstract
Dixing Liu, Jiana Zhong, Weiheng Wen, Yuting Ruan, Zhen Zhang, Jia Sun, Hong Chen Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of ChinaCorrespondence: Hong Chen; Jia SunDepartment of Endocrinology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, Guangdong, 510282, People’s Republic of ChinaTel +86 13602759769; +86 13751822925Email chenhong123@smu.edu.cn; sunjia@smu.edu.cnPurpose: Either visceral fat or muscle mass is identified to be correlated with cardiometabolic diseases, especially in type 2 diabetes (T2DM). But, the synergistical effect of visceral fat along with skeletal muscle on the risk of cardiovascular diseases (CVD) in T2DM still remains controversial. Thus, we investigated the relationship between skeletal muscle mass to visceral fat area ratio (SVR) and 10-yr CVD risk scores.Patients and Methods: A total of 291 T2DM patients aged 40– 80 years were enrolled in the current study. SVR was evaluated based on bioelectrical impedance measurements. Both Framingham risk score system and China-PAR risk model were applied to estimate future 10-yr CVD risk in T2DM population.Results: The 10-yr CVD risk scores increased with the decreased SVR tertiles in T2DM (All P< 0.001). SVR value was obviously lower in the high-risk group than that of low- or moderate-risk group (All P< 0.05). However, no significant differences were observed in BMI among different CVD risk groups. Besides, SVR was correlated with Framingham risk score (r=− 0.408; P< 0.001) and China-PAR risk score (r=− 0.336; P< 0.001). HOMA-IR, triglycerides and blood pressure were also inversely related to SVR (All P< 0.05). Furthermore, SVR value was independently correlated with both Framingham 10-yr CVD risk score (β=− 0.074, P=0.047) and China-PAR risk score (β=− 0.100, P=0.004) after adjustment for confounding factors, including age, gender, BMI, FPG, HbA1c, diabetes duration, albumin, creatinine, uric acid, smoking, blood pressure and blood lipid. The linear regression analysis was also conducted for men and women, respectively, indicating that the negative relationship between SVR and 10-yr CVD risk was observed in men but not in women.Conclusion: T2DM populations who have lower SVR value are more likely to increase CVD risk. SVR levels show marked and inverse correlation with estimated 10-yr CVD risk in T2DM, indicating that SVR could be a valuable parameter to assess the risk of CVD events in clinical practice, especially in men.Keywords: type 2 diabetes mellitus, cardiovascular diseases, skeletal muscle mass to visceral fat area ratio, risk assessment
- Published
- 2021
56. A Method for Selecting M dwarfs with an Increased Likelihood of Unresolved Ultra-cool Companionship
- Author
-
Cook, N. J., Pinfield, D. J., Marocco, F., Burningham, B., Jones, H. R. A., Frith, J., Zhong, J., Luo, A. L., Qi, Z. X., Lucas, P. W., Gromadzki, M., Day-Jones, A. C., Kurtev, R. G., Guo, Y. X., Wang, Y. F., Bai, Y., Yi, Z. P., and Smart, R. L.
- Subjects
Astrophysics - Solar and Stellar Astrophysics ,Astrophysics - Astrophysics of Galaxies ,Astrophysics - Instrumentation and Methods for Astrophysics - Abstract
Locating ultra-cool companions to M dwarfs is important for constraining low-mass formation models, the measurement of sub-stellar dynamical masses and radii, and for testing ultra-cool evolutionary models. We present an optimised method for identifying M dwarfs which may have unresolved ultra-cool companions. We construct a catalogue of 440,694 candidates, from WISE, 2MASS and SDSS, based on optical and near-infrared colours and reduced proper motion. With strict reddening, photometric and quality constraints we isolate a sub-sample of 36,898 M dwarfs and search for possible mid-infrared M dwarf + ultra-cool dwarf candidates by comparing M dwarfs which have similar optical/near-infrared colours (chosen for their sensitivity to effective temperature and metallicity). We present 1,082 M dwarf + ultra-cool dwarf candidates for follow-up. Using simulated ultra-cool dwarf companions to M dwarfs, we estimate that the occurrence of unresolved ultra-cool companions amongst our M dwarf + ultra-cool dwarf candidates should be at least four times the average for our full M dwarf catalogue. We discuss possible contamination and bias and predict yields of candidates based on our simulations., Comment: 11 pages, 10 figures, (9 pages of appendices) accepted for publication in MNRAS
- Published
- 2016
- Full Text
- View/download PDF
57. Carbon Kagome lattice and orbital frustration-induced metal-insulator transition for optoelectronics
- Author
-
Chen, Yuanping, Sun, Y. Y., Wang, H., West, D., Xie, Yuee, Zhong, J., Meunier, V., Cohen, Marvin L., and Zhang, S. B.
- Subjects
Condensed Matter - Materials Science - Abstract
A three-dimensional elemental carbon Kagome lattice (CKL), made of only fourfold coordinated carbon atoms, is proposed based on first-principles calculations. Despite the existence of 60{\deg} bond angles in the triangle rings, widely perceived to be energetically unfavorable, the CKL is found to display exceptional stability comparable to that of C60. The system allows us to study the effects of triangular frustration on the electronic properties of realistic solids, and it demonstrates a metal-insulator transition from that of graphene to a direct gap semiconductor in the visible blue region. By minimizing s-p orbital hybridization, which is an intrinsic property of carbon, not only the band edge states become nearly purely frustrated p states, but also the band structure is qualitatively different from any known bulk elemental semiconductors. For example, the optical properties are similar to those of direct-gap semiconductors GaN and ZnO, whereas the effective masses are comparable or smaller than those of Si.
- Published
- 2015
- Full Text
- View/download PDF
58. Photoelectrochemical self-powered photodetector based on 2D liquid-exfoliated bismuth nanosheets: with novel structures for portability and flexibility
- Author
-
Wang, B., Zhou, Y., Huang, Z., Qiao, H., Duan, C., Ren, X., Wang, Z., Zhong, J., and Qi, X.
- Published
- 2021
- Full Text
- View/download PDF
59. GDC-0326 Enhances the Effects of 5-Fu in Colorectal Cancer Cells by Inducing Necroptotic Death
- Author
-
Zhang Z, Ju F, Chen F, Wu H, Chen J, Zhong J, Shao L, Zheng S, Wang L, and Xue M
- Subjects
gdc-0326 ,5-fluorouracil ,colorectal cancer ,combination therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Zizhen Zhang,1– 3,* Fangyu Ju,1– 3,* Fei Chen,1– 3 Haoyue Wu,4 Jingyu Chen,1– 3 Jing Zhong,1– 3 Liming Shao,1– 3 Sheng Zheng,1– 3 Liangjing Wang,1– 3 Meng Xue1– 3 1Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310020, People’s Republic of China; 2Institution of Gastroenterology, Zhejiang University, Hangzhou, 310000, People’s Republic of China; 3Zhejiang University Cancer Center, Hangzhou, 310000, People’s Republic of China; 4Institute of Genetics and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310012, People’s Republic of China*These authors contributed equally to this workCorrespondence: Meng Xue; Liangjing Wang Email xuemeng@zju.edu.cn; wangljzju@zju.edu.cnAim: Chemoresistance to 5-fluorouracil (5-Fu) is common in colorectal cancer (CRC). Programmed necrosis (necroptosis) is an alternative form of programmed cell death regulated by receptor-interacting protein kinase (RIPK) 1 and 3, assumed as a novel target of cancer therapy. In this study, we aimed to explore whether a novel small molecular agent GDC-0326 could facilitate the effect of 5-Fu through necroptosis.Main Methods: Cell Counting Kit-8 (CCK-8) assay and colony formation were performed to confirm the function of GDC-0326 in CRC cells. Western blot and immunofluorescence were conducted to measure the altered expressions of RIPK1/RIPK3 induced by GDC-0326. Subcutaneous tumor models were used to evaluate the chemotherapeutic effects and concomitant side effects of GDC-0326 in vivo.Key Findings: We found that GDC-0326 effectively suppressed the growth of CRC cells in a dose-dependent manner. The induction of necroptosis by GDC-0326 was correlated with the modulation of RIPK1 and RIPK3. Necrostatin-1 and GSK-872, inhibitors of RIPK1 and RIPK3, respectively, could rescue the cell death induced by GDC-0326. In addition, in vitro and in vivo studies showed that 5-Fu plus GDC-0326 evinced a better antitumor efficacy by suppressing tumor growth and increasing tumor necrosis with no increased toxicity.Significance: This study demonstrates that GDC-0326 plus 5-Fu has augmented antitumor efficacy and acceptable safety, which might be a promising therapeutic strategy for CRC patients in the future.Keywords: GDC-0326, 5-fluorouracil, colorectal cancer, combination therapy
- Published
- 2021
60. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
- Author
-
Tefferi, A, Al-Ali, H, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M, Ribrag, V, Schiller, G, Vannucchi, A, Zhou, D, Reiser, D, Zhong, J, and Gale, R
- Subjects
Adult ,Aged ,Aged ,80 and over ,Biomarkers ,Erythrocyte Transfusion ,Female ,Humans ,Immunologic Factors ,Male ,Middle Aged ,Myeloproliferative Disorders ,Phenotype ,Primary Myelofibrosis ,Thalidomide ,Treatment Outcome ,Workflow - Abstract
RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. The objective of this study was to determine the rates of RBC-transfusion independence after therapy with pomalidomide vs placebo in persons with MPN-associated myelofibrosis and RBC-transfusion dependence. Two hundred and fifty-two subjects (intent-to-treat (ITT) population) including 229 subjects confirmed by central review (modified ITT population) were randomly assigned (2:1) to pomalidomide or placebo. Trialists and subjects were blinded to treatment allocation. Primary end point was proportion of subjects achieving RBC-transfusion independence within 6 months. One hundred and fifty-two subjects received pomalidomide and 77 placebo. Response rates were 16% (95% confidence interval (CI), 11, 23%) vs 16% (8, 26%; P=0.87). Response in the pomalidomide cohort was associated with ⩽4 U RBC/28 days (odds ratio (OR)=3.1; 0.9, 11.1), age ⩽65 (OR=2.3; 0.9, 5.5) and type of MPN-associated myelofibrosis (OR=2.6; 0.7, 9.5). Responses in the placebo cohort were associated with ⩽4 U RBC/28 days (OR=8.6; 0.9, 82.3), white blood cell at randomization >25 × 109/l (OR=4.9; 0.8, 28.9) and interval from diagnosis to randomization >2 years (OR=4.9; 1.1, 21.9). Pomalidomide was associated with increased rates of oedema and neutropenia but these adverse effects were manageable. Pomalidomide and placebo had similar RBC-transfusion-independence response rates in persons with MPN-associated RBC-transfusion dependence.
- Published
- 2017
61. Searching for Classical Be Stars from the LAMOST DR1
- Author
-
Lin, C. C., Hou, J. L., Chen, L., Shao, Z. Y., Zhong, J., and Yu, P. C.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
We report on searching for Classical B-type emission-line (CBe) stars from the first data release (DR1) of the Large Sky Area Multi-Object fiber Spectroscopic Telescope (LAMOST; also named the Guoshoujing Telescope). A total of 192 (12 known CBes) objects were identified as CBe candidates with prominent He~I~$\lambda4387$, He~I~$\lambda4471$, and Mg~II~$\lambda4481$ absorption lines, as well as H$\beta$~$\lambda4861$ and H$\alpha$~$\lambda6563$ emission lines. These candidates significantly increases current CBe sample of about 8\%. Most of the CBe candidates are distributed at the Galactic Anti-Center due to the LAMOST observing strategy. Only two of CBes are in the star clusters with ages of 15.8 and 398~Myr, respectively., Comment: 7 pages, 3 figures, accepted by RAA
- Published
- 2015
62. Functional MRI Correlates of Sleep Quality in HIV
- Author
-
Venkataraman A, Zhuang Y, Marsella J, Tivarus ME, Qiu X, Wang L, Zhong J, and Schifitto G
- Subjects
hiv ,fmri ,sleep quality ,functional connectivity ,Psychiatry ,RC435-571 ,Neurophysiology and neuropsychology ,QP351-495 - Abstract
Arun Venkataraman,1 Yuchuan Zhuang,2 Jennifer Marsella,3 Madalina E Tivarus,4,5 Xing Qiu,6 Lu Wang,6 Jianhui Zhong,1,4 Giovanni Schifitto3,4 1Department of Physics and Astronomy, University of Rochester, Rochester, NY, USA; 2Department of Electrical and Computer Engineering, University of Rochester, Rochester, NY, USA; 3Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA; 4Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA; 5Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, USA; 6Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USACorrespondence: Arun Venkataraman Email Arun_Venkataraman@urmc.rochester.eduObjective: To examine resting-state functional MRI (rs-fMRI) networks related to sleep in the context of HIV infection.Methods: rs-fMRI data were collected in 40 HIV-infected (HIV+) individuals at baseline (treatment-naive), 12 week (post-treatment) and one year timepoints. A group of 50 age-matched HIV-negative (HIV-) individuals were also imaged at baseline and one year timepoints. The Pittsburgh Sleep Quality Index (PSQI) questionnaire was administered at all timepoints. Using group independent component analysis (ICA), maps of functional networks were generated from fMRI data; from these, sleep-related networks were selected. A generalized linear model (GLM) was used to analyze if these networks were significantly associated with the PSQI score, and if this relationship was influenced by HIV status/treatment or timepoint.Results: HIV+ individuals had significantly lower PSQI score after treatment (p=0.022). Networks extracted from group ICA analysis included the anterior and posterior default mode network (DMN), central executive network (CEN), bilateral frontoparietal networks (FPNs), and the anterior cingulate cortex salience network (ACC SN). We found the posterior DMN, right FPN, and ACC SN GLMs showed significantly higher goodness-of-fit after incorporating PSQI data (p = 0.0204, 0.044, 0.044, respectively). Furthermore, the correlation between ACC SN and posterior DMN connectivity was significantly decreased in the HIV+ cohort.Conclusion: Functional networks such as the DMN, FPN, CEN, and ACC SN are altered in poor sleep, as measured by the PSQI score. Furthermore, the relationship between these networks and PSQI is different in the HIV+ and HIV- populations.Keywords: HIV, fMRI, sleep quality, functional connectivity
- Published
- 2021
63. Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
- Author
-
Zhang C, Zhong J, Chen WX, Zhang XY, Li YH, Zhou TY, Zou YJ, Lan C, Li L, Lai ZP, Feng H, and Hu R
- Subjects
angiotensin-converting enzyme inhibitor ,angiotensin ii receptor blocker ,inflammation ,intracerebral hemorrhage ,ich-associated pneumonia ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Chao Zhang, Jun Zhong, Wei-Xiang Chen, Xu-Yang Zhang, Yu-Hong Li, Teng-Yuan Zhou, Yong-Jie Zou, Chuan Lan, Lan Li, Zhao-Pan Lai, Hua Feng, Rong Hu Department of Neurosurgery and Key Laboratory of Neurotrauma, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, People’s Republic of ChinaCorrespondence: Rong Hu; Hua Feng Email huchrong@tmmu.edu.cn; fenghua8888@vip.163.comBackground: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in animal models. However, the role of ACEIs and ARBs in ICH patients with hypertension remains unresolved in clinic. The aim of the present study is to evaluate the effect of ACEIs/ARBs on ICH patients with hypertension using a retrospective, single-center data analysis.Methods: ICH patients diagnosed by computerized tomographic (CT) at Southwest Hospital, Third Military Medical University were included in the present research from January 2015 to December 2019. According to the medical history for the usage of antihypertensive drugs, patients were assigned into either ACEIs/ARBs group or non-ACEIs/ARBs group. Demographics, clinical baseline, radiological documents and treatments were collected and these data were statistically analyzed between the two groups.Results: A total of 635 ICH patients with hypertension were included and allocated into 2 groups according to the usage of antihypertensive drugs: 281 in the ACEIs/ARBs group and 354 in the non-ACEIs/ARBs group. The results presented that the 3-months mortality and prevalence of ICH-associated pneumonia were lower in ACEIs/ARBs group than that in non-ACEIs/ARBs group (5.0% vs 11.9%, p=0.002; 58.4% vs 66.7%, p=0.031). While, there was no significant difference in favorable outcome (40.2% vs 33.9%, p=0.101) between the two groups. Furthermore, patients in ACEIs/ARBs group exhibited significantly less perihematomal edema volume on days 3 (23.5 ± 14.4 versus 28.7 ± 20.1 mL, p=0.045) and 7 (21.0 ± 13.7 versus 25.7 ± 17.6 mL, p=0.044), compared to that in non- ACEIs/ARBs group.Conclusion: The usage of ACEIs/ARBs helps decrease mortality, perihematomal edema volume, and prevalence of ICH-associated pneumonia in ICH patients with hypertension.Keywords: angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, inflammation, intracerebral hemorrhage, ICH-associated pneumonia
- Published
- 2021
64. An Application for Thermodynamic Calculation of AuxAg1 –x-Fluid Equilibria: Super-Pure Native Gold in Woxi Au–Sb–W Deposit, Western Hunan, China
- Author
-
Liang, Y., Zhong, J. S., Pei, Q. M., and Hoshino, K.
- Published
- 2021
- Full Text
- View/download PDF
65. ACAT2 Promotes Cell Proliferation and Associates with Malignant Progression in Colorectal Cancer [Corrigendum]
- Author
-
Weng M, Zhang H, Hou W, Sun Z, Zhong J, and Miao C
- Subjects
acat2 ,cell proliferation ,malignant progression ,colorectal cancer. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Weng M, Zhang H, Hou W, Sun Z, Zhong J, Miao C. Onco Targets Ther. 2020;13:3477–3488. The authors have advised Figures 4A and 5K are incorrect. The correct Figures 4 and 5 are shown in Download Article. The authors apologize for these errors and advise that this does not affect the results of the paper. Read the original article
- Published
- 2021
66. Erratum to: Search for single top-quark production via flavour-changing neutral currents at 8 TeV with the ATLAS detector
- Author
-
Aad, G., Abbott, B., Abdallah, J., Abdinov, O., Aben, R., Abolins, M., AbouZeid, O. S., Abramowicz, H., Abreu, H., Abreu, R., Abulaiti, Y., Acharya, B. S., Adamczyk, L., Adams, D. L., Adelman, J., Adomeit, S., Adye, T., Affolder, A. A., Agatonovic-Jovin, T., Agricola, J., Aguilar-Saavedra, J. A., Ahlen, S. P., Ahmadov, F., Aielli, G., Akerstedt, H., Åkesson, T. P. A., Akimov, A. V., Alberghi, G. L., Albert, J., Albrand, S., Alconada Verzini, M. J., Aleksa, M., Aleksandrov, I. N., Alexa, C., Alexander, G., Alexopoulos, T., Alhroob, M., Alimonti, G., Alio, L., Alison, J., Alkire, S. P., Allbrooke, B. M. M., Allport, P. P., Aloisio, A., Alonso, A., Alonso, F., Alpigiani, C., Altheimer, A., Alvarez Gonzalez, B., Álvarez Piqueras, D., Alviggi, M. G., Amadio, B. T., Amako, K., Amaral Coutinho, Y., Amelung, C., Amidei, D., Amor Dos Santos, S. P., Amorim, A., Amoroso, S., Amram, N., Amundsen, G., Anastopoulos, C., Ancu, L. S., Andari, N., Andeen, T., Anders, C. F., Anders, G., Anders, J. K., Anderson, K. J., Andreazza, A., Andrei, V., Angelidakis, S., Angelozzi, I., Anger, P., Angerami, A., Anghinolfi, F., Anisenkov, A. V., Anjos, N., Annovi, A., Antonelli, M., Antonov, A., Antos, J., Anulli, F., Aoki, M., Aperio Bella, L., Arabidze, G., Arai, Y., Araque, J. P., Arce, A. T. H., Arduh, F. A., Arguin, J-F., Argyropoulos, S., Arik, M., Armbruster, A. J., Arnaez, O., Arnal, V., Arnold, H., Arratia, M., Arslan, O., Artamonov, A., Artoni, G., Asai, S., Asbah, N., Ashkenazi, A., Åsman, B., Asquith, L., Assamagan, K., Astalos, R., Atkinson, M., Atlay, N. B., Augsten, K., Aurousseau, M., Avolio, G., Axen, B., Ayoub, M. K., Azuelos, G., Baak, M. A., Baas, A. E., Baca, M. J., Bacci, C., Bachacou, H., Bachas, K., Backes, M., Backhaus, M., Bagiacchi, P., Bagnaia, P., Bai, Y., Bain, T., Baines, J. T., Baker, O. K., Baldin, E. M., Balek, P., Balestri, T., Balli, F., Banas, E., Banerjee, Sw., Bannoura, A. A. E., Bansil, H. S., Barak, L., Barberio, E. L., Barberis, D., Barbero, M., Barillari, T., Barisonzi, M., Barklow, T., Barlow, N., Barnes, S. L., Barnett, B. M., Barnett, R. M., Barnovska, Z., Baroncelli, A., Barone, G., Barr, A. J., Barreiro, F., Barreiro Guimarães da Costa, J., Bartoldus, R., Barton, A. E., Bartos, P., Basalaev, A., Bassalat, A., Basye, A., Bates, R. L., Batista, S. J., Batley, J. R., Battaglia, M., Bauce, M., Bauer, F., Bawa, H. S., Beacham, J. B., Beattie, M. D., Beau, T., Beauchemin, P. H., Beccherle, R., Bechtle, P., Beck, H. P., Becker, K., Becker, M., Beckingham, M., Becot, C., Beddall, A. J., Beddall, A., Bednyakov, V. A., Bee, C. P., Beemster, L. J., Beermann, T. A., Begel, M., Behr, J. K., Belanger-Champagne, C., Bell, W. H., Bella, G., Bellagamba, L., Bellerive, A., Bellomo, M., Belotskiy, K., Beltramello, O., Benary, O., Benchekroun, D., Bender, M., Bendtz, K., Benekos, N., Benhammou, Y., Benhar Noccioli, E., Benitez Garcia, J. A., Benjamin, D. P., Bensinger, J. R., Bentvelsen, S., Beresford, L., Beretta, M., Berge, D., Bergeaas Kuutmann, E., Berger, N., Berghaus, F., Beringer, J., Bernard, C., Bernard, N. R., Bernius, C., Bernlochner, F. U., Berry, T., Berta, P., Bertella, C., Bertoli, G., Bertolucci, F., Bertsche, C., Bertsche, D., Besana, M. I., Besjes, G. J., Bessidskaia Bylund, O., Bessner, M., Besson, N., Betancourt, C., Bethke, S., Bevan, A. J., Bhimji, W., Bianchi, R. M., Bianchini, L., Bianco, M., Biebel, O., Biedermann, D., Bieniek, S. P., Biglietti, M., Bilbao De Mendizabal, J., Bilokon, H., Bindi, M., Binet, S., Bingul, A., Bini, C., Biondi, S., Black, C. W., Black, J. E., Black, K. M., Blackburn, D., Blair, R. E., Blanchard, J.-B., Blanco, J. E., Blazek, T., Bloch, I., Blocker, C., Blum, W., Blumenschein, U., Bobbink, G. J., Bobrovnikov, V. S., Bocchetta, S. S., Bocci, A., Bock, C., Boehler, M., Bogaerts, J. A., Bogavac, D., Bogdanchikov, A. G., Bohm, C., Boisvert, V., Bold, T., Boldea, V., Boldyrev, A. S., Bomben, M., Bona, M., Boonekamp, M., Borisov, A., Borissov, G., Borroni, S., Bortfeldt, J., Bortolotto, V., Bos, K., Boscherini, D., Bosman, M., Boudreau, J., Bouffard, J., Bouhova-Thacker, E. V., Boumediene, D., Bourdarios, C., Bousson, N., Boveia, A., Boyd, J., Boyko, I. R., Bozic, I., Bracinik, J., Brandt, A., Brandt, G., Brandt, O., Bratzler, U., Brau, B., Brau, J. E., Braun, H. M., Brazzale, S. F., Breaden Madden, W. D., Brendlinger, K., Brennan, A. J., Brenner, L., Brenner, R., Bressler, S., Bristow, K., Bristow, T. M., Britton, D., Britzger, D., Brochu, F. M., Brock, I., Brock, R., Bronner, J., Brooijmans, G., Brooks, T., Brooks, W. K., Brosamer, J., Brost, E., Brown, J., Bruckman de Renstrom, P. A., Bruncko, D., Bruneliere, R., Bruni, A., Bruni, G., Bruschi, M., Bruscino, N., Bryngemark, L., Buanes, T., Buat, Q., Buchholz, P., Buckley, A. G., Buda, S. I., Budagov, I. A., Buehrer, F., Bugge, L., Bugge, M. K., Bulekov, O., Bullock, D., Burckhart, H., Burdin, S., Burgard, C. D., Burghgrave, B., Burke, S., Burmeister, I., Busato, E., Büscher, D., Büscher, V., Bussey, P., Butler, J. M., Butt, A. I., Buttar, C. M., Butterworth, J. M., Butti, P., Buttinger, W., Buzatu, A., Buzykaev, A. R., Cabrera Urbán, S., Caforio, D., Cairo, V. M., Cakir, O., Calace, N., Calafiura, P., Calandri, A., Calderini, G., Calfayan, P., Caloba, L. P., Calvet, D., Calvet, S., Camacho Toro, R., Camarda, S., Camarri, P., Cameron, D., Caminal Armadans, R., Campana, S., Campanelli, M., Campoverde, A., Canale, V., Canepa, A., Cano Bret, M., Cantero, J., Cantrill, R., Cao, T., Capeans Garrido, M. D. M., Caprini, I., Caprini, M., Capua, M., Caputo, R., Cardarelli, R., Cardillo, F., Carli, T., Carlino, G., Carminati, L., Caron, S., Carquin, E., Carrillo-Montoya, G. D., Carter, J. R., Carvalho, J., Casadei, D., Casado, M. P., Casolino, M., Castaneda-Miranda, E., Castelli, A., Castillo Gimenez, V., Castro, N. F., Catastini, P., Catinaccio, A., Catmore, J. R., Cattai, A., Caudron, J., Cavaliere, V., Cavalli, D., Cavalli-Sforza, M., Cavasinni, V., Ceradini, F., Cerio, B. C., Cerny, K., Cerqueira, A. S., Cerri, A., Cerrito, L., Cerutti, F., Cerv, M., Cervelli, A., Cetin, S. A., Chafaq, A., Chakraborty, D., Chalupkova, I., Chang, P., Chapman, J. D., Charlton, D. G., Chau, C. C., Chavez Barajas, C. A., Cheatham, S., Chegwidden, A., Chekanov, S., Chekulaev, S. V., Chelkov, G. A., Chelstowska, M. A., Chen, C., Chen, H., Chen, K., Chen, L., Chen, S., Chen, X., Chen, Y., Cheng, H. C., Cheng, Y., Cheplakov, A., Cheremushkina, E., Cherkaoui El Moursli, R., Chernyatin, V., Cheu, E., Chevalier, L., Chiarella, V., Chiarelli, G., Chiodini, G., Chisholm, A. S., Chislett, R. T., Chitan, A., Chizhov, M. V., Choi, K., Chouridou, S., Chow, B. K. B., Christodoulou, V., Chromek-Burckhart, D., Chudoba, J., Chuinard, A. J., Chwastowski, J. J., Chytka, L., Ciapetti, G., Ciftci, A. K., Cinca, D., Cindro, V., Cioara, I. A., Ciocio, A., Cirotto, F., Citron, Z. H., Ciubancan, M., Clark, A., Clark, B. L., Clark, P. J., Clarke, R. N., Cleland, W., Clement, C., Coadou, Y., Cobal, M., Coccaro, A., Cochran, J., Coffey, L., Cogan, J. G., Colasurdo, L., Cole, B., Cole, S., Colijn, A. P., Collot, J., Colombo, T., Compostella, G., Conde Muiño, P., Coniavitis, E., Connell, S. H., Connelly, I. A., Consorti, V., Constantinescu, S., Conta, C., Conti, G., Conventi, F., Cooke, M., Cooper, B. D., Cooper-Sarkar, A. M., Cornelissen, T., Corradi, M., Corriveau, F., Corso-Radu, A., Cortes-Gonzalez, A., Cortiana, G., Costa, G., Costa, M. J., Costanzo, D., Côté, D., Cottin, G., Cowan, G., Cox, B. E., Cranmer, K., Cree, G., Crépé-Renaudin, S., Crescioli, F., Cribbs, W. A., Crispin Ortuzar, M., Cristinziani, M., Croft, V., Crosetti, G., Cuhadar Donszelmann, T., Cummings, J., Curatolo, M., Cuthbert, C., Czirr, H., Czodrowski, P., D’Auria, S., D’Onofrio, M., Da Cunha Sargedas De Sousa, M. J., Da Via, C., Dabrowski, W., Dafinca, A., Dai, T., Dale, O., Dallaire, F., Dallapiccola, C., Dam, M., Dandoy, J. R., Dang, N. P., Daniells, A. C., Danninger, M., Dano Hoffmann, M., Dao, V., Darbo, G., Darmora, S., Dassoulas, J., Dattagupta, A., Davey, W., David, C., Davidek, T., Davies, E., Davies, M., Davison, P., Davygora, Y., Dawe, E., Dawson, I., Daya-Ishmukhametova, R. K., De, K., de Asmundis, R., De Benedetti, A., De Castro, S., De Cecco, S., De Groot, N., de Jong, P., De la Torre, H., De Lorenzi, F., De Pedis, D., De Salvo, A., De Sanctis, U., De Santo, A., De Vivie De Regie, J. B., Dearnaley, W. J., Debbe, R., Debenedetti, C., Dedovich, D. V., Deigaard, I., Del Peso, J., Del Prete, T., Delgove, D., Deliot, F., Delitzsch, C. M., Deliyergiyev, M., Dell’Acqua, A., Dell’Asta, L., Dell’Orso, M., Della Pietra, M., della Volpe, D., Delmastro, M., Delsart, P. A., Deluca, C., DeMarco, D. A., Demers, S., Demichev, M., Demilly, A., Denisov, S. P., Derendarz, D., Derkaoui, J. E., Derue, F., Dervan, P., Desch, K., Deterre, C., Deviveiros, P. O., Dewhurst, A., Dhaliwal, S., Di Ciaccio, A., Di Ciaccio, L., Di Domenico, A., Di Donato, C., Di Girolamo, A., Di Girolamo, B., Di Mattia, A., Di Micco, B., Di Nardo, R., Di Simone, A., Di Sipio, R., Di Valentino, D., Diaconu, C., Diamond, M., Dias, F. A., Diaz, M. A., Diehl, E. B., Dietrich, J., Diglio, S., Dimitrievska, A., Dingfelder, J., Dita, P., Dita, S., Dittus, F., Djama, F., Djobava, T., Djuvsland, J. I., do Vale, M. A. B., Dobos, D., Dobre, M., Doglioni, C., Dohmae, T., Dolejsi, J., Dolezal, Z., Dolgoshein, B. A., Donadelli, M., Donati, S., Dondero, P., Donini, J., Dopke, J., Doria, A., Dova, M. T., Doyle, A. T., Drechsler, E., Dris, M., Dubreuil, E., Duchovni, E., Duckeck, G., Ducu, O. A., Duda, D., Dudarev, A., Duflot, L., Duguid, L., Dührssen, M., Dunford, M., Duran Yildiz, H., Düren, M., Durglishvili, A., Duschinger, D., Dyndal, M., Eckardt, C., Ecker, K. M., Edgar, R. C., Edson, W., Edwards, N. C., Ehrenfeld, W., Eifert, T., Eigen, G., Einsweiler, K., Ekelof, T., El Kacimi, M., Ellert, M., Elles, S., Ellinghaus, F., Elliot, A. A., Ellis, N., Elmsheuser, J., Elsing, M., Emeliyanov, D., Enari, Y., Endner, O. C., Endo, M., Erdmann, J., Ereditato, A., Ernis, G., Ernst, J., Ernst, M., Errede, S., Ertel, E., Escalier, M., Esch, H., Escobar, C., Esposito, B., Etienvre, A. I., Etzion, E., Evans, H., Ezhilov, A., Fabbri, L., Facini, G., Fakhrutdinov, R. M., Falciano, S., Falla, R. J., Faltova, J., Fang, Y., Fanti, M., Farbin, A., Farilla, A., Farooque, T., Farrell, S., Farrington, S. M., Farthouat, P., Fassi, F., Fassnacht, P., Fassouliotis, D., Faucci Giannelli, M., Favareto, A., Fayard, L., Federic, P., Fedin, O. L., Fedorko, W., Feigl, S., Feligioni, L., Feng, C., Feng, E. J., Feng, H., Fenyuk, A. B., Feremenga, L., Fernandez Martinez, P., Fernandez Perez, S., Ferrando, J., Ferrari, A., Ferrari, P., Ferrari, R., Ferreira de Lima, D. E., Ferrer, A., Ferrere, D., Ferretti, C., Ferretto Parodi, A., Fiascaris, M., Fiedler, F., Filipčič, A., Filipuzzi, M., Filthaut, F., Fincke-Keeler, M., Finelli, K. D., Fiolhais, M. C. N., Fiorini, L., Firan, A., Fischer, A., Fischer, C., Fischer, J., Fisher, W. C., Fitzgerald, E. A., Flaschel, N., Fleck, I., Fleischmann, P., Fleischmann, S., Fletcher, G. T., Fletcher, G., Fletcher, R. R. M., Flick, T., Floderus, A., Flores Castillo, L. R., Flowerdew, M. J., Formica, A., Forti, A., Fournier, D., Fox, H., Fracchia, S., Francavilla, P., Franchini, M., Francis, D., Franconi, L., Franklin, M., Frate, M., Fraternali, M., Freeborn, D., French, S. T., Friedrich, F., Froidevaux, D., Frost, J. A., Fukunaga, C., Fullana Torregrosa, E., Fulsom, B. G., Fusayasu, T., Fuster, J., Gabaldon, C., Gabizon, O., Gabrielli, A., Gabrielli, A., Gach, G. P., Gadatsch, S., Gadomski, S., Gagliardi, G., Gagnon, P., Galea, C., Galhardo, B., Gallas, E. J., Gallop, B. J., Gallus, P., Galster, G., Gan, K. K., Gao, J., Gao, Y., Gao, Y. S., Garay Walls, F. M., Garberson, F., García, C., García Navarro, J. E., Garcia-Sciveres, M., Gardner, R. W., Garelli, N., Garonne, V., Gatti, C., Gaudiello, A., Gaudio, G., Gaur, B., Gauthier, L., Gauzzi, P., Gavrilenko, I. L., Gay, C., Gaycken, G., Gazis, E. N., Ge, P., Gecse, Z., Gee, C. N. P., Geich-Gimbel, Ch., Geisler, M. P., Gemme, C., Genest, M. H., Gentile, S., George, M., George, S., Gerbaudo, D., Gershon, A., Ghasemi, S., Ghazlane, H., Giacobbe, B., Giagu, S., Giangiobbe, V., Giannetti, P., Gibbard, B., Gibson, S. M., Gilchriese, M., Gillam, T. P. S., Gillberg, D., Gilles, G., Gingrich, D. M., Giokaris, N., Giordani, M. P., Giorgi, F. M., Giorgi, F. M., Giraud, P. F., Giromini, P., Giugni, D., Giuliani, C., Giulini, M., Gjelsten, B. K., Gkaitatzis, S., Gkialas, I., Gkougkousis, E. L., Gladilin, L. K., Glasman, C., Glatzer, J., Glaysher, P. C. F., Glazov, A., Goblirsch-Kolb, M., Goddard, J. R., Godlewski, J., Goldfarb, S., Golling, T., Golubkov, D., Gomes, A., Gonçalo, R., Goncalves Pinto Firmino Da Costa, J., Gonella, L., González de la Hoz, S., Gonzalez Parra, G., Gonzalez-Sevilla, S., Goossens, L., Gorbounov, P. A., Gordon, H. A., Gorelov, I., Gorini, B., Gorini, E., Gorišek, A., Gornicki, E., Goshaw, A. T., Gössling, C., Gostkin, M. I., Goujdami, D., Goussiou, A. G., Govender, N., Gozani, E., Grabas, H. M. X., Graber, L., Grabowska-Bold, I., Gradin, P. O. J., Grafström, P., Grahn, K-J., Gramling, J., Gramstad, E., Grancagnolo, S., Gratchev, V., Gray, H. M., Graziani, E., Greenwood, Z. D., Grefe, C., Gregersen, K., Gregor, I. M., Grenier, P., Griffiths, J., Grillo, A. A., Grimm, K., Grinstein, S., Gris, Ph., Grivaz, J.-F., Grohs, J. P., Grohsjean, A., Gross, E., Grosse-Knetter, J., Grossi, G. C., Grout, Z. J., Guan, L., Guenther, J., Guescini, F., Guest, D., Gueta, O., Guido, E., Guillemin, T., Guindon, S., Gul, U., Gumpert, C., Guo, J., Guo, Y., Gupta, S., Gustavino, G., Gutierrez, P., Gutierrez Ortiz, N. G., Gutschow, C., Guyot, C., Gwenlan, C., Gwilliam, C. B., Haas, A., Haber, C., Hadavand, H. K., Haddad, N., Haefner, P., Hageböck, S., Hajduk, Z., Hakobyan, H., Haleem, M., Haley, J., Hall, D., Halladjian, G., Hallewell, G. D., Hamacher, K., Hamal, P., Hamano, K., Hamilton, A., Hamity, G. N., Hamnett, P. G., Han, L., Hanagaki, K., Hanawa, K., Hance, M., Hanke, P., Hanna, R., Hansen, J. B., Hansen, J. D., Hansen, M. C., Hansen, P. H., Hara, K., Hard, A. S., Harenberg, T., Hariri, F., Harkusha, S., Harrington, R. D., Harrison, P. F., Hartjes, F., Hasegawa, M., Hasegawa, Y., Hasib, A., Hassani, S., Haug, S., Hauser, R., Hauswald, L., Havranek, M., Hawkes, C. M., Hawkings, R. J., Hawkins, A. D., Hayashi, T., Hayden, D., Hays, C. P., Hays, J. M., Hayward, H. S., Haywood, S. J., Head, S. J., Heck, T., Hedberg, V., Heelan, L., Heim, S., Heim, T., Heinemann, B., Heinrich, L., Hejbal, J., Helary, L., Hellman, S., Hellmich, D., Helsens, C., Henderson, J., Henderson, R. C. W., Heng, Y., Hengler, C., Henkelmann, S., Henrichs, A., Henriques Correia, A. M., Henrot-Versille, S., Herbert, G. H., Hernández Jiménez, Y., Herrberg-Schubert, R., Herten, G., Hertenberger, R., Hervas, L., Hesketh, G. G., Hessey, N. P., Hetherly, J. W., Hickling, R., Higón-Rodriguez, E., Hill, E., Hill, J. C., Hiller, K. H., Hillier, S. J., Hinchliffe, I., Hines, E., Hinman, R. R., Hirose, M., Hirschbuehl, D., Hobbs, J., Hod, N., Hodgkinson, M. C., Hodgson, P., Hoecker, A., Hoeferkamp, M. R., Hoenig, F., Hohlfeld, M., Hohn, D., Holmes, T. R., Homann, M., Hong, T. M., Hooft van Huysduynen, L., Hopkins, W. H., Horii, Y., Horton, A. J., Hostachy, J-Y., Hou, S., Hoummada, A., Howard, J., Howarth, J., Hrabovsky, M., Hristova, I., Hrivnac, J., Hryn’ova, T., Hrynevich, A., Hsu, C., Hsu, P. J., Hsu, S.-C., Hu, D., Hu, Q., Hu, X., Huang, Y., Hubacek, Z., Hubaut, F., Huegging, F., Huffman, T. B., Hughes, E. W., Hughes, G., Huhtinen, M., Hülsing, T. A., Huseynov, N., Huston, J., Huth, J., Iacobucci, G., Iakovidis, G., Ibragimov, I., Iconomidou-Fayard, L., Ideal, E., Idrissi, Z., Iengo, P., Igonkina, O., Iizawa, T., Ikegami, Y., Ikematsu, K., Ikeno, M., Ilchenko, Y., Iliadis, D., Ilic, N., Ince, T., Introzzi, G., Ioannou, P., Iodice, M., Iordanidou, K., Ippolito, V., Irles Quiles, A., Isaksson, C., Ishino, M., Ishitsuka, M., Ishmukhametov, R., Issever, C., Istin, S., Iturbe Ponce, J. M., Iuppa, R., Ivarsson, J., Iwanski, W., Iwasaki, H., Izen, J. M., Izzo, V., Jabbar, S., Jackson, B., Jackson, M., Jackson, P., Jaekel, M. R., Jain, V., Jakobs, K., Jakobsen, S., Jakoubek, T., Jakubek, J., Jamin, D. O., Jana, D. K., Jansen, E., Jansky, R., Janssen, J., Janus, M., Jarlskog, G., Javadov, N., Javůrek, T., Jeanty, L., Jejelava, J., Jeng, G.-Y., Jennens, D., Jenni, P., Jentzsch, J., Jeske, C., Jézéquel, S., Ji, H., Jia, J., Jiang, Y., Jiggins, S., Jimenez Pena, J., Jin, S., Jinaru, A., Jinnouchi, O., Joergensen, M. D., Johansson, P., Johns, K. A., Jon-And, K., Jones, G., Jones, R. W. L., Jones, T. J., Jongmanns, J., Jorge, P. M., Joshi, K. D., Jovicevic, J., Ju, X., Jung, C. A., Jussel, P., Juste Rozas, A., Kaci, M., Kaczmarska, A., Kado, M., Kagan, H., Kagan, M., Kahn, S. J., Kajomovitz, E., Kalderon, C. W., Kama, S., Kamenshchikov, A., Kanaya, N., Kaneti, S., Kantserov, V. A., Kanzaki, J., Kaplan, B., Kaplan, L. S., Kapliy, A., Kar, D., Karakostas, K., Karamaoun, A., Karastathis, N., Kareem, M. J., Karentzos, E., Karnevskiy, M., Karpov, S. N., Karpova, Z. M., Karthik, K., Kartvelishvili, V., Karyukhin, A. N., Kashif, L., Kass, R. D., Kastanas, A., Kataoka, Y., Kato, C., Katre, A., Katzy, J., Kawagoe, K., Kawamoto, T., Kawamura, G., Kazama, S., Kazanin, V. F., Keeler, R., Kehoe, R., Keller, J. S., Kempster, J. J., Keoshkerian, H., Kepka, O., Kerševan, B. P., Kersten, S., Keyes, R. A., Khalil-zada, F., Khandanyan, H., Khanov, A., Kharlamov, A. G., Khoo, T. J., Khovanskiy, V., Khramov, E., Khubua, J., Kido, S., Kim, H. Y., Kim, S. H., Kim, Y. K., Kimura, N., Kind, O. M., King, B. T., King, M., King, S. B., Kirk, J., Kiryunin, A. E., Kishimoto, T., Kisielewska, D., Kiss, F., Kiuchi, K., Kivernyk, O., Kladiva, E., Klein, M. H., Klein, M., Klein, U., Kleinknecht, K., Klimek, P., Klimentov, A., Klingenberg, R., Klinger, J. A., Klioutchnikova, T., Kluge, E.-E., Kluit, P., Kluth, S., Knapik, J., Kneringer, E., Knoops, E. B. F. G., Knue, A., Kobayashi, A., Kobayashi, D., Kobayashi, T., Kobel, M., Kocian, M., Kodys, P., Koffas, T., Koffeman, E., Kogan, L. A., Kohlmann, S., Kohout, Z., Kohriki, T., Koi, T., Kolanoski, H., Koletsou, I., Komar, A. A., Komori, Y., Kondo, T., Kondrashova, N., Köneke, K., König, A. C., Kono, T., Konoplich, R., Konstantinidis, N., Kopeliansky, R., Koperny, S., Köpke, L., Kopp, A. K., Korcyl, K., Kordas, K., Korn, A., Korol, A. A., Korolkov, I., Korolkova, E. V., Kortner, O., Kortner, S., Kosek, T., Kostyukhin, V. V., Kotov, V. M., Kotwal, A., Kourkoumeli-Charalampidi, A., Kourkoumelis, C., Kouskoura, V., Koutsman, A., Kowalewski, R., Kowalski, T. Z., Kozanecki, W., Kozhin, A. S., Kramarenko, V. A., Kramberger, G., Krasnopevtsev, D., Krasny, M. W., Krasznahorkay, A., Kraus, J. K., Kravchenko, A., Kreiss, S., Kretz, M., Kretzschmar, J., Kreutzfeldt, K., Krieger, P., Krizka, K., Kroeninger, K., Kroha, H., Kroll, J., Kroseberg, J., Krstic, J., Kruchonak, U., Krüger, H., Krumnack, N., Kruse, A., Kruse, M. C., Kruskal, M., Kubota, T., Kucuk, H., Kuday, S., Kuehn, S., Kugel, A., Kuger, F., Kuhl, A., Kuhl, T., Kukhtin, V., Kukla, R., Kulchitsky, Y., Kuleshov, S., Kuna, M., Kunigo, T., Kupco, A., Kurashige, H., Kurochkin, Y. A., Kus, V., Kuwertz, E. S., Kuze, M., Kvita, J., Kwan, T., Kyriazopoulos, D., La Rosa, A., La Rosa Navarro, J. L., La Rotonda, L., Lacasta, C., Lacava, F., Lacey, J., Lacker, H., Lacour, D., Lacuesta, V. R., Ladygin, E., Lafaye, R., Laforge, B., Lagouri, T., Lai, S., Lambourne, L., Lammers, S., Lampen, C. L., Lampl, W., Lançon, E., Landgraf, U., Landon, M. P. J., Lang, V. S., Lange, J. C., Lankford, A. J., Lanni, F., Lantzsch, K., Lanza, A., Laplace, S., Lapoire, C., Laporte, J. F., Lari, T., Lasagni Manghi, F., Lassnig, M., Laurelli, P., Lavrijsen, W., Law, A. T., Laycock, P., Lazovich, T., Le Dortz, O., Le Guirriec, E., Le Menedeu, E., LeBlanc, M., LeCompte, T., Ledroit-Guillon, F., Lee, C. A., Lee, S. C., Lee, L., Lefebvre, G., Lefebvre, M., Legger, F., Leggett, C., Lehan, A., Lehmann Miotto, G., Lei, X., Leight, W. A., Leisos, A., Leister, A. G., Leite, M. A. L., Leitner, R., Lellouch, D., Lemmer, B., Leney, K. J. C., Lenz, T., Lenzi, B., Leone, R., Leone, S., Leonidopoulos, C., Leontsinis, S., Leroy, C., Lester, C. G., Levchenko, M., Levêque, J., Levin, D., Levinson, L. J., Levy, M., Lewis, A., Leyko, A. M., Leyton, M., Li, B., Li, H., Li, H. L., Li, L., Li, L., Li, S., Li, X., Li, Y., Liang, Z., Liao, H., Liberti, B., Liblong, A., Lichard, P., Lie, K., Liebal, J., Liebig, W., Limbach, C., Limosani, A., Lin, S. C., Lin, T. H., Linde, F., Lindquist, B. E., Linnemann, J. T., Lipeles, E., Lipniacka, A., Lisovyi, M., Liss, T. M., Lissauer, D., Lister, A., Litke, A. M., Liu, B., Liu, D., Liu, H., Liu, J., Liu, J. B., Liu, K., Liu, L., Liu, M., Liu, M., Liu, Y., Livan, M., Lleres, A., Llorente Merino, J., Lloyd, S. L., Lo Sterzo, F., Lobodzinska, E., Loch, P., Lockman, W. S., Loebinger, F. K., Loevschall-Jensen, A. E., Loginov, A., Lohse, T., Lohwasser, K., Lokajicek, M., Long, B. A., Long, J. D., Long, R. E., Looper, K. A., Lopes, L., Lopez Mateos, D., Lopez Paredes, B., Lopez Paz, I., Lorenz, J., Lorenzo Martinez, N., Losada, M., Lösel, P. J., Lou, X., Lounis, A., Love, J., Love, P. A., Lu, N., Lubatti, H. J., Luci, C., Lucotte, A., Luehring, F., Lukas, W., Luminari, L., Lundberg, O., Lund-Jensen, B., Lynn, D., Lysak, R., Lytken, E., Ma, H., Ma, L. L., Maccarrone, G., Macchiolo, A., Macdonald, C. M., Maček, B., Machado Miguens, J., Macina, D., Madaffari, D., Madar, R., Maddocks, H. J., Mader, W. F., Madsen, A., Maeda, J., Maeland, S., Maeno, T., Maevskiy, A., Magradze, E., Mahboubi, K., Mahlstedt, J., Maiani, C., Maidantchik, C., Maier, A. A., Maier, T., Maio, A., Majewski, S., Makida, Y., Makovec, N., Malaescu, B., Malecki, Pa., Maleev, V. P., Malek, F., Mallik, U., Malon, D., Malone, C., Maltezos, S., Malyshev, V. M., Malyukov, S., Mamuzic, J., Mancini, G., Mandelli, B., Mandelli, L., Mandić, I., Mandrysch, R., Maneira, J., Manfredini, A., Manhaes de Andrade Filho, L., Manjarres Ramos, J., Mann, A., Manousakis-Katsikakis, A., Mansoulie, B., Mantifel, R., Mantoani, M., Mapelli, L., March, L., Marchiori, G., Marcisovsky, M., Marino, C. P., Marjanovic, M., Marley, D. E., Marroquim, F., Marsden, S. P., Marshall, Z., Marti, L. F., Marti-Garcia, S., Martin, B., Martin, T. A., Martin, V. J., Martin dit Latour, B., Martinez, M., Martin-Haugh, S., Martoiu, V. S., Martyniuk, A. C., Marx, M., Marzano, F., Marzin, A., Masetti, L., Mashimo, T., Mashinistov, R., Masik, J., Maslennikov, A. L., Massa, I., Massa, L., Massol, N., Mastrandrea, P., Mastroberardino, A., Masubuchi, T., Mättig, P., Mattmann, Jm., Maurer, J., Maxfield, S. J., Maximov, D. A., Mazini, R., Mazza, S. M., Mazzaferro, L., Mc Goldrick, G., Mc Kee, S. P., McCarn, A., McCarthy, R. L., McCarthy, T. G., McCubbin, N. A., McFarlane, K. W., Mcfayden, J. A., Mchedlidze, G., McMahon, S. J., McPherson, R. A., Medinnis, M., Meehan, S., Mehlhase, S., Mehta, A., Meier, K., Meineck, C., Meirose, B., Mellado Garcia, B. R., Meloni, F., Mengarelli, A., Menke, S., Meoni, E., Mercurio, K. M., Mergelmeyer, S., Mermod, P., Merola, L., Meroni, C., Merritt, F. S., Messina, A., Metcalfe, J., Mete, A. S., Meyer, C., Meyer, C., Meyer, J-P., Meyer, J., Meyer Zu Theenhausen, H., Middleton, R. P., Miglioranzi, S., Mijović, L., Mikenberg, G., Mikestikova, M., Mikuž, M., Milesi, M., Milic, A., Miller, D. W., Mills, C., Milov, A., Milstead, D. A., Minaenko, A. A., Minami, Y., Minashvili, I. A., Mincer, A. I., Mindur, B., Mineev, M., Ming, Y., Mir, L. M., Mitani, T., Mitrevski, J., Mitsou, V. A., Miucci, A., Miyagawa, P. S., Mjörnmark, J. U., Moa, T., Mochizuki, K., Mohapatra, S., Mohr, W., Molander, S., Moles-Valls, R., Monden, R., Mönig, K., Monini, C., Monk, J., Monnier, E., Montejo Berlingen, J., Monticelli, F., Monzani, S., Moore, R. W., Morange, N., Moreno, D., Moreno Llácer, M., Morettini, P., Mori, D., Morii, M., Morinaga, M., Morisbak, V., Moritz, S., Morley, A. K., Mornacchi, G., Morris, J. D., Mortensen, S. S., Morton, A., Morvaj, L., Mosidze, M., Moss, J., Motohashi, K., Mount, R., Mountricha, E., Mouraviev, S. V., Moyse, E. J. W., Muanza, S., Mudd, R. D., Mueller, F., Mueller, J., Mueller, R. S. P., Mueller, T., Muenstermann, D., Mullen, P., Mullier, G. A., Murillo Quijada, J. A., Murray, W. J., Musheghyan, H., Musto, E., Myagkov, A. G., Myska, M., Nachman, B. P., Nackenhorst, O., Nadal, J., Nagai, K., Nagai, R., Nagai, Y., Nagano, K., Nagarkar, A., Nagasaka, Y., Nagata, K., Nagel, M., Nagy, E., Nairz, A. M., Nakahama, Y., Nakamura, K., Nakamura, T., Nakano, I., Namasivayam, H., Naranjo Garcia, R. F., Narayan, R., Narrias Villar, D. I., Naumann, T., Navarro, G., Nayyar, R., Neal, H. A., Nechaeva, P. Yu., Neep, T. J., Nef, P. D., Negri, A., Negrini, M., Nektarijevic, S., Nellist, C., Nelson, A., Nemecek, S., Nemethy, P., Nepomuceno, A. A., Nessi, M., Neubauer, M. S., Neumann, M., Neves, R. M., Nevski, P., Newman, P. R., Nguyen, D. H., Nickerson, R. B., Nicolaidou, R., Nicquevert, B., Nielsen, J., Nikiforou, N., Nikiforov, A., Nikolaenko, V., Nikolic-Audit, I., Nikolopoulos, K., Nilsen, J. K., Nilsson, P., Ninomiya, Y., Nisati, A., Nisius, R., Nobe, T., Nomachi, M., Nomidis, I., Nooney, T., Norberg, S., Nordberg, M., Novgorodova, O., Nowak, S., Nozaki, M., Nozka, L., Ntekas, K., Nunes Hanninger, G., Nunnemann, T., Nurse, E., Nuti, F., O’Brien, B. J., O’grady, F., O’Neil, D. C., O’Shea, V., Oakham, F. G., Oberlack, H., Obermann, T., Ocariz, J., Ochi, A., Ochoa, I., Ochoa-Ricoux, J. P., Oda, S., Odaka, S., Ogren, H., Oh, A., Oh, S. H., Ohm, C. C., Ohman, H., Oide, H., Okamura, W., Okawa, H., Okumura, Y., Okuyama, T., Olariu, A., Olivares Pino, S. A., Oliveira Damazio, D., Oliver Garcia, E., Olszewski, A., Olszowska, J., Onofre, A., Onogi, K., Onyisi, P. U. E., Oram, C. J., Oreglia, M. J., Oren, Y., Orestano, D., Orlando, N., Oropeza Barrera, C., Orr, R. S., Osculati, B., Ospanov, R., Otero y Garzon, G., Otono, H., Ouchrif, M., Ould-Saada, F., Ouraou, A., Oussoren, K. P., Ouyang, Q., Ovcharova, A., Owen, M., Owen, R. E., Ozcan, V. E., Ozturk, N., Pachal, K., Pacheco Pages, A., Padilla Aranda, C., Pagáčová, M., Pagan Griso, S., Paganis, E., Paige, F., Pais, P., Pajchel, K., Palacino, G., Palestini, S., Palka, M., Pallin, D., Palma, A., Pan, Y. B., Panagiotopoulou, E., Pandini, C. E., Panduro Vazquez, J. G., Pani, P., Panitkin, S., Pantea, D., Paolozzi, L., Papadopoulou, Th. D., Papageorgiou, K., Paramonov, A., Paredes Hernandez, D., Parker, M. A., Parker, K. A., Parodi, F., Parsons, J. A., Parzefall, U., Pasqualucci, E., Passaggio, S., Pastore, F., Pastore, Fr., Pásztor, G., Pataraia, S., Patel, N. D., Pater, J. R., Pauly, T., Pearce, J., Pearson, B., Pedersen, L. E., Pedersen, M., Pedraza Lopez, S., Pedro, R., Peleganchuk, S. V., Pelikan, D., Penc, O., Peng, C., Peng, H., Penning, B., Penwell, J., Perepelitsa, D. V., Perez Codina, E., Pérez García-Estañ, M. T., Perini, L., Pernegger, H., Perrella, S., Peschke, R., Peshekhonov, V. D., Peters, K., Peters, R. F. Y., Petersen, B. A., Petersen, T. C., Petit, E., Petridis, A., Petridou, C., Petroff, P., Petrolo, E., Petrucci, F., Pettersson, N. E., Pezoa, R., Phillips, P. W., Piacquadio, G., Pianori, E., Picazio, A., Piccaro, E., Piccinini, M., Pickering, M. A., Piegaia, R., Pignotti, D. T., Pilcher, J. E., Pilkington, A. D., Pina, J., Pinamonti, M., Pinfold, J. L., Pingel, A., Pires, S., Pirumov, H., Pitt, M., Pizio, C., Plazak, L., Pleier, M.-A., Pleskot, V., Plotnikova, E., Plucinski, P., Pluth, D., Poettgen, R., Poggioli, L., Pohl, D., Polesello, G., Poley, A., Policicchio, A., Polifka, R., Polini, A., Pollard, C. S., Polychronakos, V., Pommès, K., Pontecorvo, L., Pope, B. G., Popeneciu, G. A., Popovic, D. S., Poppleton, A., Pospisil, S., Potamianos, K., Potrap, I. N., Potter, C. J., Potter, C. T., Poulard, G., Poveda, J., Pozdnyakov, V., Pralavorio, P., Pranko, A., Prasad, S., Prell, S., Price, D., Price, L. E., Primavera, M., Prince, S., Proissl, M., Prokofiev, K., Prokoshin, F., Protopapadaki, E., Protopopescu, S., Proudfoot, J., Przybycien, M., Ptacek, E., Puddu, D., Pueschel, E., Puldon, D., Purohit, M., Puzo, P., Qian, J., Qin, G., Qin, Y., Quadt, A., Quarrie, D. R., Quayle, W. B., Queitsch-Maitland, M., Quilty, D., Raddum, S., Radeka, V., Radescu, V., Radhakrishnan, S. K., Radloff, P., Rados, P., Ragusa, F., Rahal, G., Rajagopalan, S., Rammensee, M., Rangel-Smith, C., Rauscher, F., Rave, S., Ravenscroft, T., Raymond, M., Read, A. L., Readioff, N. P., Rebuzzi, D. M., Redelbach, A., Redlinger, G., Reece, R., Reeves, K., Rehnisch, L., Reichert, J., Reisin, H., Relich, M., Rembser, C., Ren, H., Renaud, A., Rescigno, M., Resconi, S., Rezanova, O. L., Reznicek, P., Rezvani, R., Richter, R., Richter, S., Richter-Was, E., Ricken, O., Ridel, M., Rieck, P., Riegel, C. J., Rieger, J., Rifki, O., Rijssenbeek, M., Rimoldi, A., Rinaldi, L., Ristić, B., Ritsch, E., Riu, I., Rizatdinova, F., Rizvi, E., Robertson, S. H., Robichaud-Veronneau, A., Robinson, D., Robinson, J. E. M., Robson, A., Roda, C., Roe, S., Røhne, O., Rolli, S., Romaniouk, A., Romano, M., Romano Saez, S. M., Romero Adam, E., Rompotis, N., Ronzani, M., Roos, L., Ros, E., Rosati, S., Rosbach, K., Rose, P., Rosendahl, P. L., Rosenthal, O., Rossetti, V., Rossi, E., Rossi, L. P., Rosten, J. H. N., Rosten, R., Rotaru, M., Roth, I., Rothberg, J., Rousseau, D., Royon, C. R., Rozanov, A., Rozen, Y., Ruan, X., Rubbo, F., Rubinskiy, I., Rud, V. I., Rudolph, C., Rudolph, M. S., Rühr, F., Ruiz-Martinez, A., Rurikova, Z., Rusakovich, N. A., Ruschke, A., Russell, H. L., Rutherfoord, J. P., Ruthmann, N., Ryabov, Y. F., Rybar, M., Rybkin, G., Ryder, N. C., Saavedra, A. F., Sabato, G., Sacerdoti, S., Saddique, A., Sadrozinski, H. F-W., Sadykov, R., Safai Tehrani, F., Sahinsoy, M., Saimpert, M., Saito, T., Sakamoto, H., Sakurai, Y., Salamanna, G., Salamon, A., Salazar Loyola, J. E., Saleem, M., Salek, D., Sales De Bruin, P. H., Salihagic, D., Salnikov, A., Salt, J., Salvatore, D., Salvatore, F., Salvucci, A., Salzburger, A., Sammel, D., Sampsonidis, D., Sanchez, A., Sánchez, J., Sanchez Martinez, V., Sandaker, H., Sandbach, R. L., Sander, H. G., Sanders, M. P., Sandhoff, M., Sandoval, C., Sandstroem, R., Sankey, D. P. C., Sannino, M., Sansoni, A., Santoni, C., Santonico, R., Santos, H., Santoyo Castillo, I., Sapp, K., Sapronov, A., Saraiva, J. G., Sarrazin, B., Sasaki, O., Sasaki, Y., Sato, K., Sauvage, G., Sauvan, E., Savage, G., Savard, P., Sawyer, C., Sawyer, L., Saxon, J., Sbarra, C., Sbrizzi, A., Scanlon, T., Scannicchio, D. A., Scarcella, M., Scarfone, V., Schaarschmidt, J., Schacht, P., Schaefer, D., Schaefer, R., Schaeffer, J., Schaepe, S., Schaetzel, S., Schäfer, U., Schaffer, A. C., Schaile, D., Schamberger, R. D., Scharf, V., Schegelsky, V. A., Scheirich, D., Schernau, M., Schiavi, C., Schillo, C., Schioppa, M., Schlenker, S., Schmieden, K., Schmitt, C., Schmitt, S., Schmitt, S., Schneider, B., Schnellbach, Y. J., Schnoor, U., Schoeffel, L., Schoening, A., Schoenrock, B. D., Schopf, E., Schorlemmer, A. L. S., Schott, M., Schouten, D., Schovancova, J., Schramm, S., Schreyer, M., Schroeder, C., Schuh, N., Schultens, M. J., Schultz-Coulon, H.-C., Schulz, H., Schumacher, M., Schumm, B. A., Schune, Ph., Schwanenberger, C., Schwartzman, A., Schwarz, T. A., Schwegler, Ph., Schweiger, H., Schwemling, Ph., Schwienhorst, R., Schwindling, J., Schwindt, T., Sciacca, F. G., Scifo, E., Sciolla, G., Scuri, F., Scutti, F., Searcy, J., Sedov, G., Sedykh, E., Seema, P., Seidel, S. C., Seiden, A., Seifert, F., Seixas, J. M., Sekhniaidze, G., Sekhon, K., Sekula, S. J., Seliverstov, D. M., Semprini-Cesari, N., Serfon, C., Serin, L., Serkin, L., Serre, T., Sessa, M., Seuster, R., Severini, H., Sfiligoj, T., Sforza, F., Sfyrla, A., Shabalina, E., Shamim, M., Shan, L. Y., Shang, R., Shank, J. T., Shapiro, M., Shatalov, P. B., Shaw, K., Shaw, S. M., Shcherbakova, A., Shehu, C. Y., Sherwood, P., Shi, L., Shimizu, S., Shimmin, C. O., Shimojima, M., Shiyakova, M., Shmeleva, A., Shoaleh Saadi, D., Shochet, M. J., Shojaii, S., Shrestha, S., Shulga, E., Shupe, M. A., Shushkevich, S., Sicho, P., Sidebo, P. E., Sidiropoulou, O., Sidorov, D., Sidoti, A., Siegert, F., Sijacki, Dj., Silva, J., Silver, Y., Silverstein, S. B., Simak, V., Simard, O., Simic, Lj., Simion, S., Simioni, E., Simmons, B., Simon, D., Sinervo, P., Sinev, N. B., Sioli, M., Siragusa, G., Sisakyan, A. N., Sivoklokov, S. Yu., Sjölin, J., Sjursen, T. B., Skinner, M. B., Skottowe, H. P., Skubic, P., Slater, M., Slavicek, T., Slawinska, M., Sliwa, K., Smakhtin, V., Smart, B. H., Smestad, L., Smirnov, S. Yu., Smirnov, Y., Smirnova, L. N., Smirnova, O., Smith, M. N. K., Smith, R. W., Smizanska, M., Smolek, K., Snesarev, A. A., Snidero, G., Snyder, S., Sobie, R., Socher, F., Soffer, A., Soh, D. A., Sokhrannyi, G., Solans, C. A., Solar, M., Solc, J., Soldatov, E. Yu., Soldevila, U., Solodkov, A. A., Soloshenko, A., Solovyanov, O. V., Solovyev, V., Sommer, P., Song, H. Y., Soni, N., Sood, A., Sopczak, A., Sopko, B., Sopko, V., Sorin, V., Sosa, D., Sosebee, M., Sotiropoulou, C. L., Soualah, R., Soukharev, A. M., South, D., Sowden, B. C., Spagnolo, S., Spalla, M., Spangenberg, M., Spanò, F., Spearman, W. R., Sperlich, D., Spettel, F., Spighi, R., Spigo, G., Spiller, L. A., Spousta, M., Spreitzer, T., Denis, R. D. St., Stabile, A., Staerz, S., Stahlman, J., Stamen, R., Stamm, S., Stanecka, E., Stanescu, C., Stanescu-Bellu, M., Stanitzki, M. M., Stapnes, S., Starchenko, E. A., Stark, J., Staroba, P., Starovoitov, P., Staszewski, R., Steinberg, P., Stelzer, B., Stelzer, H. J., Stelzer-Chilton, O., Stenzel, H., Stewart, G. A., Stillings, J. A., Stockton, M. C., Stoebe, M., Stoicea, G., Stolte, P., Stonjek, S., Stradling, A. R., Straessner, A., Stramaglia, M. E., Strandberg, J., Strandberg, S., Strandlie, A., Strauss, E., Strauss, M., Strizenec, P., Ströhmer, R., Strom, D. M., Stroynowski, R., Strubig, A., Stucci, S. A., Stugu, B., Styles, N. A., Su, D., Su, J., Subramaniam, R., Succurro, A., Sugaya, Y., Suk, M., Sulin, V. V., Sultansoy, S., Sumida, T., Sun, S., Sun, X., Sundermann, J. E., Suruliz, K., Susinno, G., Sutton, M. R., Suzuki, S., Svatos, M., Swiatlowski, M., Sykora, I., Sykora, T., Ta, D., Taccini, C., Tackmann, K., Taenzer, J., Taffard, A., Tafirout, R., Taiblum, N., Takai, H., Takashima, R., Takeda, H., Takeshita, T., Takubo, Y., Talby, M., Talyshev, A. A., Tam, J. Y. C., Tan, K. G., Tanaka, J., Tanaka, R., Tanaka, S., Tannenwald, B. B., Tannoury, N., Tapprogge, S., Tarem, S., Tarrade, F., Tartarelli, G. F., Tas, P., Tasevsky, M., Tashiro, T., Tassi, E., Tavares Delgado, A., Tayalati, Y., Taylor, F. E., Taylor, G. N., Taylor, W., Teischinger, F. A., Teixeira Dias Castanheira, M., Teixeira-Dias, P., Temming, K. K., Temple, D., Ten Kate, H., Teng, P. K., Teoh, J. J., Tepel, F., Terada, S., Terashi, K., Terron, J., Terzo, S., Testa, M., Teuscher, R. J., Theveneaux-Pelzer, T., Thomas, J. P., Thomas-Wilsker, J., Thompson, E. N., Thompson, P. D., Thompson, R. J., Thompson, A. S., Thomsen, L. A., Thomson, E., Thomson, M., Thun, R. P., Tibbetts, M. J., Ticse Torres, R. E., Tikhomirov, V. O., Tikhonov, Yu. A., Timoshenko, S., Tiouchichine, E., Tipton, P., Tisserant, S., Todome, K., Todorov, T., Todorova-Nova, S., Tojo, J., Tokár, S., Tokushuku, K., Tollefson, K., Tolley, E., Tomlinson, L., Tomoto, M., Tompkins, L., Toms, K., Torrence, E., Torres, H., Torró Pastor, E., Toth, J., Touchard, F., Tovey, D. R., Trefzger, T., Tremblet, L., Tricoli, A., Trigger, I. M., Trincaz-Duvoid, S., Tripiana, M. F., Trischuk, W., Trocmé, B., Troncon, C., Trottier-McDonald, M., Trovatelli, M., True, P., Truong, L., Trzebinski, M., Trzupek, A., Tsarouchas, C., Tseng, J. C-L., Tsiareshka, P. V., Tsionou, D., Tsipolitis, G., Tsirintanis, N., Tsiskaridze, S., Tsiskaridze, V., Tskhadadze, E. G., Tsukerman, I. I., Tsulaia, V., Tsuno, S., Tsybychev, D., Tudorache, A., Tudorache, V., Tuna, A. N., Tupputi, S. A., Turchikhin, S., Turecek, D., Turra, R., Turvey, A. J., Tuts, P. M., Tykhonov, A., Tylmad, M., Tyndel, M., Ueda, I., Ueno, R., Ughetto, M., Ugland, M., Ukegawa, F., Unal, G., Undrus, A., Unel, G., Ungaro, F. C., Unno, Y., Unverdorben, C., Urban, J., Urquijo, P., Urrejola, P., Usai, G., Usanova, A., Vacavant, L., Vacek, V., Vachon, B., Valderanis, C., Valencic, N., Valentinetti, S., Valero, A., Valery, L., Valkar, S., Valladolid Gallego, E., Vallecorsa, S., Valls Ferrer, J. A., Van Den Wollenberg, W., Van Der Deijl, P. C., van der Geer, R., van der Graaf, H., van Eldik, N., van Gemmeren, P., Van Nieuwkoop, J., van Vulpen, I., van Woerden, M. C., Vanadia, M., Vandelli, W., Vanguri, R., Vaniachine, A., Vannucci, F., Vardanyan, G., Vari, R., Varnes, E. W., Varol, T., Varouchas, D., Vartapetian, A., Varvell, K. E., Vazeille, F., Vazquez Schroeder, T., Veatch, J., Veloce, L. M., Veloso, F., Velz, T., Veneziano, S., Ventura, A., Ventura, D., Venturi, M., Venturi, N., Venturini, A., Vercesi, V., Verducci, M., Verkerke, W., Vermeulen, J. C., Vest, A., Vetterli, M. C., Viazlo, O., Vichou, I., Vickey, T., Vickey Boeriu, O. E., Viehhauser, G. H. A., Viel, S., Vigne, R., Villa, M., Villaplana Perez, M., Vilucchi, E., Vincter, M. G., Vinogradov, V. B., Vivarelli, I., Vives Vaque, F., Vlachos, S., Vladoiu, D., Vlasak, M., Vogel, M., Vokac, P., Volpi, G., Volpi, M., von der Schmitt, H., von Radziewski, H., von Toerne, E., Vorobel, V., Vorobev, K., Vos, M., Voss, R., Vossebeld, J. H., Vranjes, N., Vranjes Milosavljevic, M., Vrba, V., Vreeswijk, M., Vuillermet, R., Vukotic, I., Vykydal, Z., Wagner, P., Wagner, W., Wahlberg, H., Wahrmund, S., Wakabayashi, J., Walder, J., Walker, R., Walkowiak, W., Wang, C., Wang, F., Wang, H., Wang, H., Wang, J., Wang, J., Wang, K., Wang, R., Wang, S. M., Wang, T., Wang, T., Wang, X., Wanotayaroj, C., Warburton, A., Ward, C. P., Wardrope, D. R., Washbrook, A., Wasicki, C., Watkins, P. M., Watson, A. T., Watson, I. J., Watson, M. F., Watts, G., Watts, S., Waugh, B. M., Webb, S., Weber, M. S., Weber, S. W., Webster, J. S., Weidberg, A. R., Weinert, B., Weingarten, J., Weiser, C., Weits, H., Wells, P. S., Wenaus, T., Wengler, T., Wenig, S., Wermes, N., Werner, M., Werner, P., Wessels, M., Wetter, J., Whalen, K., Wharton, A. M., White, A., White, M. J., White, R., White, S., Whiteson, D., Wickens, F. J., Wiedenmann, W., Wielers, M., Wienemann, P., Wiglesworth, C., Wiik-Fuchs, L. A. M., Wildauer, A., Wilkens, H. G., Williams, H. H., Williams, S., Willis, C., Willocq, S., Wilson, A., Wilson, J. A., Wingerter-Seez, I., Winklmeier, F., Winter, B. T., Wittgen, M., Wittkowski, J., Wollstadt, S. J., Wolter, M. W., Wolters, H., Wosiek, B. K., Wotschack, J., Woudstra, M. J., Wozniak, K. W., Wu, M., Wu, M., Wu, S. L., Wu, X., Wu, Y., Wyatt, T. R., Wynne, B. M., Xella, S., Xu, D., Xu, L., Yabsley, B., Yacoob, S., Yakabe, R., Yamada, M., Yamaguchi, D., Yamaguchi, Y., Yamamoto, A., Yamamoto, S., Yamanaka, T., Yamauchi, K., Yamazaki, Y., Yan, Z., Yang, H., Yang, H., Yang, Y., Yao, W-M., Yasu, Y., Yatsenko, E., Yau Wong, K. H., Ye, J., Ye, S., Yeletskikh, I., Yen, A. L., Yildirim, E., Yorita, K., Yoshida, R., Yoshihara, K., Young, C., Young, C. J. S., Youssef, S., Yu, D. R., Yu, J., Yu, J. M., Yu, J., Yuan, L., Yuen, S. P. Y., Yurkewicz, A., Yusuff, I., Zabinski, B., Zaidan, R., Zaitsev, A. M., Zalieckas, J., Zaman, A., Zambito, S., Zanello, L., Zanzi, D., Zeitnitz, C., Zeman, M., Zemla, A., Zeng, Q., Zengel, K., Zenin, O., Ženiš, T., Zerwas, D., Zhang, D., Zhang, F., Zhang, H., Zhang, J., Zhang, L., Zhang, R., Zhang, X., Zhang, Z., Zhao, X., Zhao, Y., Zhao, Z., Zhemchugov, A., Zhong, J., Zhou, B., Zhou, C., Zhou, L., Zhou, L., Zhou, M., Zhou, N., Zhu, C. G., Zhu, H., Zhu, J., Zhu, Y., Zhuang, X., Zhukov, K., Zibell, A., Zieminska, D., Zimine, N. I., Zimmermann, C., Zimmermann, S., Zinonos, Z., Zinser, M., Ziolkowski, M., Živković, L., Zobernig, G., Zoccoli, A., zur Nedden, M., Zurzolo, G., and Zwalinski, L.
- Published
- 2022
- Full Text
- View/download PDF
67. Comparison of the efficacy of two surgical procedures on adenoidal hypertrophy in children
- Author
-
Huang, H., Zhang, L., Zhang, Q., Zhong, J., Fu, L., and Mou, Y.
- Published
- 2020
- Full Text
- View/download PDF
68. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
- Author
-
Martinez-Morilla, Sandra, McGuire, John, Gaule, Patricia, Moore, Lauren, Acs, Balazs, Cougot, Delphine, Gown, Allen M., Yaziji, Hadi, Wang, Wei-Lien, Cartun, Richard W., Hornick, Jason L., Sholl, Lynette M., Qiu, Jingxin, Mino-Kenudson, Mari, Yi, Eunhee S., Beasley, Mary Beth, Merrick, Daniel T., Ambaye, Abiy B., Zhang, Zhong J., Walker, Jill, and Rimm, David L.
- Published
- 2020
- Full Text
- View/download PDF
69. Tuning of Critical Temperature and Aging Effect of Ti Films For Superconducting Transition-Edge Sensors
- Author
-
Zhang, W., primary, Wang, Z., additional, Li, P. Z., additional, Zhong, J. Q., additional, Ma, Q. X., additional, Feng, Z. F., additional, Zhou, K. M., additional, Miao, W., additional, Ren, Y., additional, Yao, Q. J., additional, Li, J., additional, and Shi, S. C., additional
- Published
- 2023
- Full Text
- View/download PDF
70. Ang1/Tie2/VE-Cadherin Signaling Regulates DPSCs in Vascular Maturation
- Author
-
Zhang, Y., primary, Lin, S., additional, Liu, J., additional, Chen, Q., additional, Kang, J., additional, Zhong, J., additional, Hu, M., additional, Basabrain, M.S., additional, Liang, Y., additional, Yuan, C., additional, and Zhang, C., additional
- Published
- 2023
- Full Text
- View/download PDF
71. 89P Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A single arm phase II trial
- Author
-
Ma, L., primary, Deng, Z., additional, Qi, L-N., additional, Chen, Z-S., additional, Zhang, Z-M., additional, Xiang, B-D., additional, and Zhong, J-H., additional
- Published
- 2023
- Full Text
- View/download PDF
72. Sudomotor dysfunction is associated with impaired left ventricular diastolic function in persons with type 2 diabetes: a cross-sectional study
- Author
-
Chen, X., primary, Shui, X., additional, Xu, H., additional, Peng, J., additional, Deng, H., additional, Zhong, J., additional, Wang, C., additional, Wu, J., additional, Yan, J., additional, Yao, B., additional, Xiong, Z., additional, Xu, W., additional, and Yang, X., additional
- Published
- 2023
- Full Text
- View/download PDF
73. Dapagliflozin effect on functional mitral regurgitation and myocardial remodeling (DEFORM trial)
- Author
-
Huang, Z S, primary, Fan, R, additional, Xie, P H, additional, Zhong, J L, additional, Zhang, S Z, additional, Zhuang, X D, additional, and Liao, X X, additional
- Published
- 2023
- Full Text
- View/download PDF
74. EP05.01-13 Time to Lung Cancer Diagnosis and Treatment in the Era of the COVID-19 Pandemic
- Author
-
Zhang, A.L., primary, Li, J., additional, Zhong, J., additional, Abbas, K.Z., additional, Bennett, A., additional, Wang, Q., additional, Hsu, M., additional, and Avasarala, S.K., additional
- Published
- 2023
- Full Text
- View/download PDF
75. P2.06-02 DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN)
- Author
-
Li, H., primary, Xu, H.-Y., additional, Duan, J.-C., additional, Wang, Z.-J., additional, Zhong, J., additional, Cui, Y.-Y., additional, Fang, Q., additional, Lei, S.-Y., additional, and Wang, Y., additional
- Published
- 2023
- Full Text
- View/download PDF
76. MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH STABLE ASTHMA CONTROL
- Author
-
Mehta, V., primary, Worm, M., additional, Chiesa, Z., additional, Natalie, C., additional, Dawson, Z., additional, Zhong, J., additional, Diemert, S., additional, and Boguniewicz, M., additional
- Published
- 2023
- Full Text
- View/download PDF
77. Fat to Muscle Ratio Measurements with Dual Energy X Ray Absorbtiometry
- Author
-
Chen, A., Wang, A., Broadbent, C., Zhong, J., Dilmanian, A., Zafonte, F., and Zhong, Z.
- Subjects
Physics - Medical Physics - Abstract
Accurate measurement of the fat-to-muscle ratio in animal model is important for obesity research. An efficient way to measure the fat to muscle ratio in animal model using dual-energy absorptiometry is presented in this paper. A radioactive source exciting x-ray fluorescence from a target material is used to provide the two x-ray energies needed. The x-rays, after transmitting through the sample, are measured with an energy-sensitive Ge detector. Phantoms and specimens were measured. The results showed that the method was sensitive to the fat to muscle ratios with good linearity. A standard deviation of a few percent in the fat to muscle ratio could be observed with the x-ray dose of 0.001 mGy., Comment: 17 pages, 7 figures, Nuclear Instrument Method in Physics Research, 2014
- Published
- 2014
- Full Text
- View/download PDF
78. 953P Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
- Author
-
Li, Z., primary, Li, L., additional, Cui, K., additional, Zhong, J., additional, Sun, P., additional, Zhang, C., additional, and Shi, X., additional
- Published
- 2023
- Full Text
- View/download PDF
79. Stereotactic Radiosurgery for Trigeminal Neuralgia: A Comparison of Proximal and Distal Isocenter Outcomes
- Author
-
Hopkins, B., primary, Qian, D.C., additional, Deibert, C., additional, Boulis, N., additional, Jiang, X., additional, Kahn, S.T., additional, Sudmeier, L.J., additional, Shu, H.K.G., additional, Eaton, B.R., additional, Buchwald, Z.S., additional, and Zhong, J., additional
- Published
- 2023
- Full Text
- View/download PDF
80. Bandgap Controlling of the Oxygen-Vacancy-Induced Two-Dimensional Electron Gas in SrTiO3
- Author
-
Liu, Z. Q., Lu, W., Zeng, S. W., Deng, J. W., Huang, Z., Li, C. J., Motapothula, M., Lü, W. M., Sun, L., Han, K., Zhong, J. Q., Yang, P., Bao, N. N., Chen, W., Chen, J. S., Feng, Y. P., Coey, J. M. D., Venkatesan, T., and Ariando
- Subjects
Condensed Matter - Materials Science ,Condensed Matter - Strongly Correlated Electrons ,Condensed Matter - Superconductivity - Abstract
We report very large bandgap enhancement in SrTiO3 (STO) films (fabricated by pulsed laser deposition below 800 {\deg}C), which can be up to 20% greater than the bulk value, depending on the deposition temperature. The origin is comprehensively investigated and finally attributed to Sr/Ti antisite point defects, supported by density functional theory calculations. More importantly, the bandgap enhancement can be utilized to tailor the electronic and magnetic phases of the two-dimensional electron gas (2DEG) in STO-based interface systems. For example, the oxygen-vacancy-induced 2DEG (2DEG-V) at the interface between amorphous LaAlO3 and STO films is more localized and the ferromagnetic order in the STO-film-based 2DEG-V can be clearly seen from low-temperature magnetotransport measurements. This opens an attractive path to tailor electronic, magnetic and optical properties of STO-based oxide interface systems under intensive focus in the oxide electronics community. Meanwhile, our study provides key insight into the origin of the fundamental issue that STO films are difficult to be doped into the fully metallic state by oxygen vacancies., Comment: 35 pages, 6 figures in the main text,13 figures in the supporting information. To be appearing in Advanced Materials Interfaces soon
- Published
- 2014
- Full Text
- View/download PDF
81. X-ray and EUV spectroscopy of various astrophysical and laboratory plasmas -- Collisional, photoionization and charge-exchange plasmas
- Author
-
Liang, G. Y., Li, F., Wang, F. L., Wu, Y., Zhong, J. Y., and Zhao, G.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
Several laboratory facilities were used to benchmark theoretical spectral models those extensively used by astronomical communities. However there are still many differences between astrophysical environments and laboratory miniatures that can be archived. Here we setup a spectral analysis system for astrophysical and laboratory (SASAL) plasmas to make a bridge between them, and investigate the effects from non-thermal electrons, contribution from metastable level-population on level populations and charge stage distribution for coronal-like, photoionized, and geocoronal plasmas. Test applications to laboratory measurement (i.e. EBIT plasma) and astrophysical observation (i.e. Comet, Cygnus X-3) are presented. Time evolution of charge stage and level population are also explored for collisional and photoionized plasmas., Comment: 11 Figures, 3 Tables, Accepted by ApJ on Jan. 23, 2014. Astrophysical Journal 2014
- Published
- 2014
- Full Text
- View/download PDF
82. TP53INP2 Modulates Epithelial-to-Mesenchymal Transition via the GSK-3β/β-Catenin/Snail1 Pathway in Bladder Cancer Cells
- Author
-
Zhou Z, Liu X, Li Y, Li J, Deng W, Zhong J, Chen L, Zeng X, Wang G, Zhu J, and Fu B
- Subjects
tp53inp2 ,β-catenin ,snail1 ,emt ,bladder cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Zhengtao Zhou,1,2,* Xiaoqiang Liu,1,2,* Yulei Li,1 Junhua Li,3 Wen Deng,1 Jian Zhong,4 Luyao Chen,1 Yu Li,1 Xiantao Zeng,5 Gongxian Wang,1,2 Jingyu Zhu,3 Bin Fu1,2 1Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China; 2Jiangxi Institute of Urology, Nanchang, People’s Republic of China; 3Department of Urology, Third Hospital of Hangzhou, Hangzhou, People’s Republic of China; 4Department of Surgery, Nankang District Chinese Medicine Hospital, Ganzhou, People’s Republic of China; 5Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Bin FuDepartment of Urology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, Jiangxi 330006, People’s Republic of ChinaTel +86 13879103861Email urofubin@sina.comJingyu ZhuDepartment of Urology, Third Hospital of Hangzhou, 38 Westlake Road, Hangzhou, Zhejiang 310009, People’s Republic of ChinaTel +86 571 87827269Email zhujingyu@126.comBackground: The tumor protein p53-inducible nuclear protein 2 (TP53INP2), an autophagy protein, is essential for autophagosome formation. The deregulation of autophagy is associated with multiple human diseases, including cancer. The present study aims to explore the role of TP53INP2 in bladder cancer.Materials and Methods: Quantitative real-time polymerase chain reaction was used to detect the mRNA level. Relative TP53INP2 protein expression was detected by immunohistochemistry and Western blot. The effect of TP53INP2 silencing on the proliferation, migration, and invasion of bladder cancer cells was investigated by CCK-8 detection kit and transwell assay. In addition, transfection and immunofluorescence were performed.Results: In this study, we report that high expression of TP53INP2 is correlated with poor patient survival in bladder cancer. Results demonstrate that the depletion of TP53INP2 inhibits the migration, invasion, and epithelial-to-mesenchymal transition (EMT) of bladder cancer cells. The underlying mechanism was explored. Results show that the TP53INP2 knockdown suppresses EMT by inhibiting the active non-phosphorylated β-catenin and decreasing the Snail1 levels. Furthermore, the glycogen synthase kinase-3 beta (GSK-3β) inhibitor IM-12 abrogates the effect of TP53INP2 silencing. Interestingly, the induction of autophagy partially abrogates the TP53INP2 knockdown-induced decrease in active β-catenin and inhibition of migration and invasion in bladder cancer cells.Conclusion: In summary, our results show that the downregulation of TP53INP2 inhibits EMT via the GSK-3β/β-catenin/Snail1 pathway in bladder cancer. The findings of this study uncover the novel role of TP53INP2 and offer new insights into bladder cancer clinical therapy.Keywords: TP53INP2, β-catenin, Snail1, EMT, bladder cancer
- Published
- 2020
83. Applying Machine Learning Models to Predict Medication Nonadherence in Crohn’s Disease Maintenance Therapy
- Author
-
Wang L, Fan R, Zhang C, Hong L, Zhang T, Chen Y, Liu K, Wang Z, and Zhong J
- Subjects
crohn’s disease ,azathioprine ,medication adherence ,maintenance therapy ,machine learning ,support vector machine ,back-propagation neural network. ,Medicine (General) ,R5-920 - Abstract
Lei Wang,1,* Rong Fan,1,* Chen Zhang,1 Liwen Hong,1 Tianyu Zhang,1 Ying Chen,2 Kai Liu,2 Zhengting Wang,1 Jie Zhong1 1Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 2CareLinker Co., Ltd., Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhengting Wang; Jie ZhongDepartment of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijiner Road, Shanghai 200025, People’s Republic of ChinaTel +86-21-64370045 ext. 600901Email Dake_wang@126.com; jimmyzj64@hotmail.comObjective: Medication adherence is crucial in the management of Crohn’s disease (CD), and yet the adherence remains low. This study aimed to develop machine learning models that can help predict CD patients of nonadherence to azathioprine (AZA), and thus assist caregivers to streamline the intervention process.Methods: This single-centered, cross-sectional study recruited 446 CD patients who have been prescribed AZA between Sep 2005 and Sep 2018. Questionnaires of medication adherence, anxiety and depression, beliefs of medication necessity and concerns, and medication knowledge were provided to patients, while other data were extracted from the electronic medical records. Two machine learning models of back-propagation neural network (BPNN) and support vector machine (SVM) were developed and compared with logistic regression (LR), and assessed by accuracy, recall, precision, F1 score and the area under the receiver operating characteristic curve (AUC).Results: The average classification accuracy and AUC of the three models were 81.6% and 0.896 for LR, 85.9% and 0.912 for BPNN, and 87.7% and 0.930 for SVM, respectively. Multivariate analysis identified four risk factors associated with AZA nonadherence: medication concern belief (OR=3.130, p< 0.001), education (OR=2.199, p< 0.001), anxiety (OR=1.549, p< 0.001) and depression (OR=1.190, p< 0.001), while medication necessity belief (OR=0.004, p< 0.001) and medication knowledge (OR=0.805, p=0.013) were protective factors.Conclusion: We developed three machine learning models and proposed an SVM model with promising accuracy in the prediction of AZA nonadherence in Chinese CD patients. The study also reconfirmed that education, psychologic distress, and medication beliefs and knowledge are correlated to AZA nonadherence.Keywords: Crohn’s disease, azathioprine, medication adherence, maintenance therapy, machine learning, support vector machine, back-propagation neural network
- Published
- 2020
84. ACAT2 Promotes Cell Proliferation and Associates with Malignant Progression in Colorectal Cancer
- Author
-
Weng M, Zhang H, Hou W, Sun Z, Zhong J, and Miao C
- Subjects
acat2 ,cell proliferation ,malignant progression ,colorectal cancer. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Meilin Weng,1,2,* Hao Zhang,1– 3,* Wenting Hou,1,2,* Zhirong Sun,1,2 Jing Zhong,1– 3 Changhong Miao1– 3 1Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People’s Republic of China; 3Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai 200032, People’s Republic of China*These authors contributed equally to this workCorrespondence: Changhong Miao; Jing ZhongDepartment of Anesthesiology, Floor 3, Building 3, No. 270 Dongan Road, Shanghai 200032 Tel +8618017317731Email whitedolphin2006@126.com; ziteng1934@163.comBackground and Aims: Colorectal cancer (CRC) is a major disease that threatens human health. It has been reported that the acyl-coenzyme A (CoA): cholesterol acyltransferase 2 (ACAT2) gene can promote the progression of hepatocellular carcinoma, but its function in CRC is still unclear. In this study, we aimed to elucidate the function of ACAT2 in CRC.Methods: Western blot and qPCR were used to detect the relative level of ACAT2 in CRC tissue and adjacent non-cancerous tissues, and then the association between ACAT2 expression and the clinicopathological features and survival of CRC patients were assessed. The expression of ACAT2 in CT26 and DLD1 cells was down-regulated by siRNA, and the effects of ACAT2 knockdown on cell proliferation were examined. The inhibitory effects of ACAT2 knockdown were further confirmed by tumor growth assays in vivo.Results: Our data showed that the expression of ACAT2 in CRC tissues was markedly higher than in adjacent non-cancerous tissues. The high expression of ACAT2 was significantly associated with tumor size, lymph node metastasis and clinical stage. The increased expression of ACAT2 was also significantly associated with worse 5-year overall survival of CRC patients. siRNA-mediated ACAT2 knockdown strongly inhibited CT26 and DLD1 cells proliferation and induced G0/G1 phase cell cycle arrest and apoptosis in these cells. Knockdown of ACAT2 expression suppressed the growth of CRC and inhibited the expression of Ki67 in vivo.Conclusion: Our study demonstrated that ACAT2 played a positive role in regulating the proliferation of CRC and may be useful as a potential biomarker and therapeutic target for this disease.Keywords: ACAT2, cell proliferation, malignant progression, colorectal cancer
- Published
- 2020
85. Oncogenic Role and Prognostic Value of MicroRNA-937-3p in Patients with Breast Cancer
- Author
-
Li D, Zhong J, Zhang G, Lin L, and Liu Z
- Subjects
mir-937-3p ,breast cancer ,proliferation ,migration ,invasion ,prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Deyu Li,1,2 Jiangming Zhong,1,2 Guifeng Zhang,1,2 Li Lin,1,2 Zhenhua Liu1,2 1Department of Medical Oncology, Provincial Clinical College, Fujian Medical University, Fuzhou 350001, People’s Republic of China; 2Department of Medical Oncology, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of ChinaCorrespondence: Zhenhua LiuDepartment of Medical Oncology, Provincial Clinical College, Fujian Medical University, No. 134 Dongjie Street, Fuzhou 350001, Fujian Province, People’s Republic of ChinaTel +86 591-88217461Email liuzhenhua6909@163.comPurpose: Breast cancer is the most common female tumor in the world. MicroRNA has been reported to play an important role in the progression of breast cancer. The purpose of this study was to explore the role of miR-937-3p in breast cancer.Patients and methods: Expression of miR-937-3p in breast cancer tissues and serums was detected from The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) and patients’ samples. Kaplan–Meier plotter identified the association between miR-937-3p and prognosis.Results: The analysis of TCGA, GEO and qRT-PCR suggested that the level of miR-937-3p was increased in breast cancer tissues and serum compared with adjacent normal breast tissues and healthy persons, respectively. The decreased expression of miR-937-3p inhibited breast cancer proliferation, migration and invasion. CCRL2 was the target of miR-937-3p. In contrast to miR-937-3p, the level of CCRL2 was decreased in breast cancer tissues. Luciferase reporter assay revealed that miR-937-3p directly bound to the 3ʹ-UTR of CCRL2. Double knockdown of CCRL2 and miR-937-3p promoted breast cancer cell proliferation, migration and invasion, suggesting that miR-937-3p promoted breast cancer cell proliferation, migration and invasion by targeting CCRL2. The Kaplan–Meier survival analysis suggested that breast cancer patients with high level of miR-937-3p or low level of CCRL2 had a reduced overall survival (OS).Conclusion: miR-937-3p plays an important role in the diagnosis and prognosis of breast cancer. Inhibition of miR-937-3p expression may be a novel targeted therapy for breast cancer.Keywords: miR-937-3p, breast cancer, proliferation, migration, invasion, prognosis
- Published
- 2019
86. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy
- Author
-
Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, and Deng Y
- Subjects
chronic hepatitis B ,high viral load ,nucleos(t)ide analogs ,virologic response ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Meijin Huang,1 Jie Zhong,2 Chunlei Lu,1 Fenglian Deng,1 Li Li,1 Yixi Nong,1 Liudan Liang,1 Houji Qin,1 Yibin Deng3 1Department of Infectious Diseases, Affiliated Hospital of Youjiang Nationalities Medical College, Baise City, Guangxi Province, People’s Republic of China; 2Department of Neurology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi Province, People’s Republic of China; 3Medical Examination Center, Affiliated Hospital of Youjiang Nationalities Medical College, Baise City, Guangxi Province, People’s Republic of ChinaCorrespondence: Houji QinThe Infectious Department of the Affiliated Hospital of Youjiang Nationalities Medical College, Baise City, Guangxi Province, People’s Republic of ChinaEmail houjiqin1964@163.comYibin DengMedical Examination Center of the Affiliated Hospital of Youjiang Nationalities Medical College, Baise City, Guangxi Province, People’s Republic of ChinaTel/fax +86 76-2802090Email dengyb75@163.comAims: Previous studies have shown that baseline high viral load is closely related to treatment response in chronic hepatitis B (CHB). This study was designed to evaluate the differences of treatment responses between de novo lamivudine (LAM) plus adefovir (ADV) combination therapy compared with entecavir monotherapy (ETV).Methods: A total of 185 HBeAg-positive CHB patients with high viral load were enrolled and assigned to the LAM+ADV group (n=90) or ETV group (n=95). Clinical variables are extracted from medical records.Results: No significant differences in baseline variables were found between the two groups before antiviral treatment. After 104 weeks of antiviral therapy, the mean HBV DNA viral load in the LAM+ADV group decreased from 8.01±0.65 log10 copies/mL to 0.41±1.04 log10 copies/mL, compared with 8.04±0.57 log10 copies/mL to 0.57±1.28 log10 copies/mL in the ETV group (P=0.35). The virological response rate of LAM+ADV group was 82.2% (74/90) at 104 weeks of treatment, and 80.0% (76/95) in the ETV group (P=0.70). For HBeAg serological responses, HBeAg loss occurred in 23.3% (21/90) and 17.9% (17/95) in the LAM+ADV group and the ETV group, respectively (P=0.36). HBeAg seroconversion was observed in 15.6% (14/90) and 15.8% (15/95) in the LAM+ADV group and ETV group, respectively (P=0.96). However, after 104 weeks of treatment, genotypic resistance was confirmed in 8 cases in the LAM+ADV group, a proportion of 8.8% (8/90), compared with an absence of genotypic resistance in the ETV group (P=0.003).Conclusion: Both de novo combination therapy of LAM+ADV and ETV monotherapy could effectively inhibit HBV replication in patients with high viral load. However, the rate of genotypic resistance in LAM+ADV treatment remains a concern. For CHB patients with high viral load, ETV treatment may be superior.Keywords: chronic hepatitis B, high viral load, nucleos(t)ide analogs, virologic response
- Published
- 2019
87. High-performance silver nanowire-based thermopolyurethane flexible conductive films
- Author
-
Zhong, J., Zhou, Z., Zhang, J., Tang, J., Wu, P., and Wang, Y.
- Published
- 2020
- Full Text
- View/download PDF
88. Synthesis of Sphere-Like Silver Nanostructures Composed of Self-Assembled Nanosheets
- Author
-
Zhong, J. J. and Wang, Y. H.
- Published
- 2020
- Full Text
- View/download PDF
89. Ti Hot Electron Bolometers with Johnson Noise Readout for Terahertz Radiation Detection
- Author
-
Gao, H., Miao, W., Wang, Z., Zhang, W., Ren, Y., Zhou, K. M., Zhong, J. Q., and Shi, S. C.
- Published
- 2020
- Full Text
- View/download PDF
90. Improving Energy Detection Efficiency of Ti-Based Superconducting Transition-Edge Sensors with Optical Cavity
- Author
-
Geng, Y., Zhang, W., Li, P. Z., Zhong, J. Q., Wang, Z., Miao, W., Ren, Y., Wang, J. F., Yao, Q. J., and Shi, S. C.
- Published
- 2020
- Full Text
- View/download PDF
91. Diagnostic value of novel biomarkers for heart failure: A meta-analysis
- Author
-
Huang, Z., Zhong, J., Ling, Y., Zhang, Y., Lin, W., Tang, L., Liu, J., and Li, S.
- Published
- 2020
- Full Text
- View/download PDF
92. The Carriers of the Interstellar Unidentified Infrared Emission Features: Constraints from the Interstellar C-H Stretching Features at 3.2-3.5 Micrometers
- Author
-
Yang, X. J., Glaser, R., Li, Aigen, and Zhong, J. X.
- Subjects
Astrophysics - Astrophysics of Galaxies - Abstract
The unidentified infrared emission (UIE) features at 3.3, 6.2, 7.7, 8.6, and 11.3 micrometer, commonly attributed to polycyclic aromatic hydrocarbon (PAH) molecules, have been recently ascribed to mixed aromatic/aliphatic organic nanoparticles. More recently, an upper limit of <9% on the aliphatic fraction (i.e., the fraction of carbon atoms in aliphatic form) of the UIE carriers based on the observed intensities of the 3.4 and 3.3 micrometer emission features by attributing them to aliphatic and aromatic C-H stretching modes, respectively, and assuming A_34./A_3.3~0.68 derived from a small set of aliphatic and aromatic compounds, where A_3.4 and A_3.3 are respectively the band strengths of the 3.4 micrometer aliphatic and 3.3 micrometer aromatic C-H bonds. To improve the estimate of the aliphatic fraction of the UIE carriers, here we analyze 35 UIE sources which exhibit both the 3.3 and 3.4 micrometer C-H features and determine I_3.4/I_3.3, the ratio of the power emitted from the 3.4 micrometer feature to that from the 3.3 micrometer feature. We derive the median ratio to be
~ 0.12. We employ density functional theory and second-order perturbation theory to compute A_3.4/A_3.3 for a range of methyl-substituted PAHs. The resulting A_3.4/A_3.3 ratio well exceeds 1.4, with an average ratio of ~1.76. By attributing the 3.4 micrometer feature exclusively to aliphatic C-H stretch (i.e., neglecting anharmonicity and superhydrogenation), we derive the fraction of C atoms in aliphatic form to be ~2%. We therefore conclude that the UIE emitters are predominantly aromatic., Comment: 14 pages, 5 figures, 1 table; accepted for publication in The Astrophysical Journal - Published
- 2013
- Full Text
- View/download PDF
93. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT
- Author
-
Brown, P. J., Zhong, J., Frood, R., Currie, S., Gilbert, A., Appelt, A. L., Sebag-Montefiore, D., and Scarsbrook, A.
- Published
- 2019
- Full Text
- View/download PDF
94. Systematic enumeration of crystalline networks with only sp2 configuration in cubic lattices
- Author
-
He, Chaoyu, Sun, L. Z., Zhang, C. X., and Zhong, J. X.
- Subjects
Condensed Matter - Materials Science - Abstract
Systematic enumeration of crystalline networks with some special topological characters is of considerable interest in both mathematics and crystallography. Based on the restriction of lattice in cubic and inequivalent nodes not exceeding three, a simple method is proposed for systematic searching for three-dimensional crystalline networks with only sp2-configuration nodes (C-sp2-TDTCNs). We systematically scan the cubic space groups from No.195 to No.230 and find many C-sp2-TDTCNs including all the previously proposed cubic ones. These C-sp2-TDTCNs are topologically intriguing and can be considered as good templates for searching carbon crystals with novel properties, predicting high pressure phases of element nitrogen and designing three-dimensional hydrocarbon crystals. Structure optimizations are considered by regrading these C-sp2-TDTCNs as carbon crystals and the corresponding energetic stability of these carbon crystals are evaluated, using the the density functional theory (DFT) based first-principle calculations. Our results are of wide interests in mathematics, condensed physics, crystallography and material science., Comment: 7 pages, 2 figures and 2 tables in the main text. We also provide a Supplementary Information including 4 figures and 3 tables
- Published
- 2013
95. Cr-K Emission Line as a Constraint on the Progenitor Properties of Supernova Remnants
- Author
-
Yang, X. J., Tsunemi, H., Lu, F. J., Li, Aigen, Xiang, F. Y., Xiao, H. P., and Zhong, J. X.
- Subjects
Astrophysics - High Energy Astrophysical Phenomena - Abstract
We perform a survey of the Cr, Mn and Fe-K emission lines in young supernova remnants (SNRs) with the Japanese X-ray astronomy satellite {\sl Suzaku}. The Cr and/or Mn emission lines are detected in 3C\,397 and 0519-69.0 for the first time. We also confirm the detection of these lines in Kepler, W49B, N103B and Cas A. We derive the line parameters (i.e., the line centroid energy, flux and equivalent width [EW]) for these six sources and perform a correlation analysis for the line center energies of Cr, Mn and Fe. Also included in the correlation analysis are Tycho and G344.7-0.1 for which the Cr, Mn and Fe-K line parameters were available in the literature through {\sl Suzaku} observations. We find that the line center energies of Cr correlates very well with that of Fe and that of Mn. This confirms our previous findings that the Cr, Mn and Fe are spatially co-located, share a similar ionization state, and have a common origin in the supernova nucleo-synthesis. We find that the ratio of the EW of the Cr emission line to that of Fe ($\EWR\equiv \EWCr/\EWFe$) provides useful constraints on the SNR progenitors and on the SN explosion mechanisms: for SNRs with $\EWR > 2%$, a type Ia origin is favored (e.g., N103B, G344.7-0.1, 3C\,397 and 0519-69.0); for SNRs with $\EWR < 2%$, they could be of either core-collpase origin or carbon-deflagration Ia origin., Comment: 17 pages, 5 figures, accepted for publication in the Astrophysical Journal
- Published
- 2013
- Full Text
- View/download PDF
96. Evidence for \eta_{c}(2S) in \psi(3686) \to \gamma K_{S}^{0}K^{\pm}\pi^{\mp}\pi^{+}\pi^{-}
- Author
-
The BESIII Collaboration, Ablikim, M., Achasov, M. N., Albayrak, O., Ambrose, D. J., An, F. F., An, Q., Bai, J. Z., Ban, Y., Becker, J., Bennett, J. V., Bertani, M., Bian, J. M., Boger, E., Bondarenko, O., Boyko, I., Briere, R. A., Bytev, V., Cai, X., Cakir, O., Calcaterra, A., Cao, G. F., Cetin, S. A., Chang, J. F., Chelkov, G., Chen, G., Chen, H. S., Chen, J. C., Chen, M. L., Chen, S. J., Chen, X., Chen, Y. B., Cheng, H. P., Chu, Y. P., Cronin-Hennessy, D., Dai, H. L., Dai, J. P., Dedovich, D., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., Ding, W. M., Ding, Y., Dong, L. Y., Dong, M. Y., Du, S. X., Fang, J., Fang, S. S., Fava, L., Feldbauer, F., Feng, C. Q., Ferroli, R. B., Fu, C. D., Fu, J. L., Gao, Y., Geng, C., Goetzen, K., Gong, W. X., Gradl, W., Greco, M., Gu, M. H., Gu, Y. T., Guan, Y. H., Guo, A. Q., Guo, L. B., Guo, Y. P., Han, Y. L., Harris, F. A., He, K. L., He, M., He, Z. Y., Held, T., Heng, Y. K., Hou, Z. L., Hu, H. M., Hu, T., Huang, G. M., Huang, G. S., Huang, J. S., Huang, X. T., Huang, Y. P., Hussain, T., Ji, C. S., Ji, Q., Ji, Q. P., Ji, X. B., Ji, X. L., Jiang, L. L., Jiang, X. S., Jiao, J. B., Jiao, Z., Jin, D. P., Jin, S., Jing, F. F., Kalantar-Nayestanaki, N., Kavatsyuk, M., Kuehn, W., Lai, W., Lange, J. S., Li, C. H., Li, Cheng, Li, Cui, Li, D. M., Li, F., Li, G., Li, H. B., Li, J. C., Li, K., Li, Lei, Li, Q. J., Li, S. L., Li, W. D., Li, W. G., Li, X. L., Li, X. N., Li, X. Q., Li, X. R., Li, Z. B., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, X. T., Liu, B. J., Liu, C. L., Liu, C. X., Liu, C. Y., Liu, F. H., Liu, Fang, Liu, Feng, Liu, H., Liu, H. H., Liu, H. M., Liu, H. W., Liu, J. P., Liu, K. Y., Liu, Kai, Liu, P. L., Liu, Q., Liu, S. B., Liu, X., Liu, Y. B., Liu, Z. A., Liu, Zhiqiang, Liu, Zhiqing, Loehner, H., Lu, G. R., Lu, H. J., Lu, J. G., Lu, Q. W., Lu, X. R., Lu, Y. P., Luo, C. L., Luo, M. X., Luo, T., Luo, X. L., Lv, M., Ma, C. L., Ma, F. C., Ma, H. L., Ma, Q. M., Ma, S., Ma, T., Ma, X. Y., Ma, Y., Maas, F. E., Maggiora, M., Malik, Q. A., Mao, Y. J., Mao, Z. P., Messchendorp, J. G., Min, J., Min, T. J., Mitchell, R. E., Mo, X. H., Morales, C. Morales, Motzko, C., Muchnoi, N. Yu., Muramatsu, H., Nefedov, Y., Nicholson, C., Nikolaev, I. B., Ning, Z., Olsen, S. L., Ouyang, Q., Pacetti, S., Park, J. W., Pelizaeus, M., Peng, H. P., Peters, K., Ping, J. L., Ping, R. G., Poling, R., Prencipe, E., Qi, M., Qian, S., Qiao, C. F., Qin, X. S., Qin, Y., Qin, Z. H., Qiu, J. F., Rashid, K. H., Rong, G., Ruan, X. D., Sarantsev, A., Schaefer, B. D., Schulze, J., Shao, M., Shen, C. P., Shen, X. Y., Sheng, H. Y., Shepherd, M. R., Song, X. Y., Spataro, S., Spruck, B., Sun, D. H., Sun, G. X., Sun, J. F., Sun, S. S., Sun, Y. J., Sun, Y. Z., Sun, Z. J., Sun, Z. T., Tang, C. J., Tang, X., Tapan, I., Thorndike, E. H., Toth, D., Ullrich, M., Varner, G. S., Wang, B., Wang, B. Q., Wang, D., Wang, D. Y., Wang, K., Wang, L. L., Wang, L. S., Wang, M., Wang, P., Wang, P. L., Wang, Q., Wang, Q. J., Wang, S. G., Wang, X. L., Wang, Y. D., Wang, Y. F., Wang, Y. Q., Wang, Z., Wang, Z. G., Wang, Z. Y., Wei, D. H., Wei, J. B., Weidenkaff, P., Wen, Q. G., Wen, S. P., Werner, M., Wiedner, U., Wu, L. H., Wu, N., Wu, S. X., Wu, W., Wu, Z., Xia, L. G., Xiao, Z. J., Xie, Y. G., Xiu, Q. L., Xu, G. F., Xu, G. M., Xu, H., Xu, Q. J., Xu, X. P., Xu, Z. R., Xue, F., Xue, Z., Yan, L., Yan, W. B., Yan, Y. H., Yang, H. X., Yang, Y., Yang, Y. X., Ye, H., Ye, M., Ye, M. H., Yu, B. X., Yu, C. X., Yu, H. W., Yu, J. S., Yu, S. P., Yuan, C. Z., Yuan, Y., Zafar, A. A., Zallo, A., Zeng, Y., Zhang, B. X., Zhang, B. Y., Zhang, C., Zhang, C. C., Zhang, D. H., Zhang, H. H., Zhang, H. Y., Zhang, J. Q., Zhang, J. W., Zhang, J. Y., Zhang, J. Z., Zhang, S. H., Zhang, X. J., Zhang, X. Y., Zhang, Y., Zhang, Y. H., Zhang, Y. S., Zhang, Z. P., Zhang, Z. Y., Zhao, G., Zhao, H. S., Zhao, J. W., Zhao, K. X., Zhao, Lei, Zhao, Ling, Zhao, M. G., Zhao, Q., Zhao, Q. Z., Zhao, S. J., Zhao, T. C., Zhao, X. H., Zhao, Y. B., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, J. P., Zheng, Y. H., Zhong, B., Zhong, J., Zhong, Z., Zhou, L., Zhou, X. K., Zhou, X. R., Zhu, C., Zhu, K., Zhu, K. J., Zhu, S. H., Zhu, X. L., Zhu, Y. C., Zhu, Y. M., Zhu, Y. S., Zhu, Z. A., Zhuang, J., Zou, B. S., and Zou, J. H.
- Subjects
High Energy Physics - Experiment - Abstract
We search for the M1 radiative transition \psi(3686) \to \gamma\eta_{c}(2S) by reconstructing the exclusive \eta_{c}(2S) \to K_{S}^{0}K^{\pm}\pi^{\mp}\pi^{+}\pi^{-} decay using 1.06 \times 10^8 \psi(3686) events collected with the BESIII detector. The signal is observed with a statistical significance of greater than 4 standard deviations. The measured mass of the \eta_{c}(2S) is 3646.9 \pm 1.6(stat) \pm 3.6(syst) MeV/c^2, and the width is 9.9 \pm 4.8(stat) \pm 2.9(syst) MeV/c^2. The product branching fraction is measured to be B(\psi(3686) \to \gamma\eta_{c}(2S)) \times B(\eta_{c}(2S) \to K_{S}^{0}K^{\pm}\pi^{\mp}\pi^{+}\pi^{-}) = (7.03 \pm 2.10(stat) \pm 0.70(syst)) \times 10^{-6}. This measurement complements a previous BESIII measurement of \psi(3686) \to \gamma\eta_{c}(2S) with \eta_{c}(2S) \to K_{S}^{0} K^{\pm}\pi^{\mp} and K^{+}K^{-}\pi^{0}.
- Published
- 2013
- Full Text
- View/download PDF
97. A Tale of Two Mysteries in Interstellar Astrophysics: The 2175 Angstrom Extinction Bump and Diffuse Interstellar Bands
- Author
-
Xiang, F. Y., Li, Aigen, and Zhong, J. X.
- Subjects
Astrophysics - Astrophysics of Galaxies - Abstract
The diffuse interstellar bands (DIBs) are ubiquitous absorption spectral features arising from the tenuous material in the space between stars -- the interstellar medium (ISM). Since their first detection nearly nine decades ago, over 400 DIBs have been observed in the visible and near-infrared wavelength range in both the Milky Way and external galaxies, both nearby and distant. However, the identity of the species responsible for these bands remains as one of the most enigmatic mysteries in astrophysics. An equally mysterious interstellar spectral signature is the 2175 Angstrom extinction bump, the strongest absorption feature observed in the ISM. Its carrier also remains unclear since its first detection 46 years ago. Polycyclic aromatic hydrocarbon (PAH) molecules have long been proposed as a candidate for DIBs as their electronic transitions occur in the wavelength range where DIBs are often found. In recent years, the 2175 Angstrom extinction bump is also often attributed to the \pi--\pi* transition in PAHs. If PAHs are indeed responsible for both the 2175 Angstrom extinction feature and DIBs, their strengths may correlate. We perform an extensive literature search for lines of sight for which both the 2175 Angstrom extinction feature and DIBs have been measured. Unfortunately, we found no correlation between the strength of the 2175 Angstrom feature and the equivalent widths of the strongest DIBs. A possible explanation might be that DIBs are produced by small free gas-phase PAH molecules and ions, while the 2175 Angstrom bump is mainly from large PAHs or PAH clusters in condensed phase so that there is no tight correlation between DIBs and the 2175 Angstrom bump., Comment: 45 pages, 3 figures, 4 tables, published in ApJ
- Published
- 2012
- Full Text
- View/download PDF
98. Precision measurements of branching fractions for $ \psi'\to\pi^0 J\psi$ and $\eta J\psi$
- Author
-
Ablikim, M., Achasov, M. N., Albayrak, O., Ambrose, D. J., An, F. F., An, Q., Bai, J. Z., Ban, Y., Becker, J., Bennett, J. V., Bertani, M., Bian, J. M., Bondarenko, E. Boger O., Boyko, I., Briere, R. A., Bytev, V., Cai, X., Cakir, O., Calcaterra, A., Cao, G. F., CetinB, S. A., Chang, J. F., Chen, G. Chelkov G., Chen, H. S., Chen, J. C., Chen, M. L., Chen, S. J., Chen, X., Chen, Y. B., Cheng, H. P., Chu, Y. P., Coccetti, F., Cronin-Hennessy, D., Dai, H. L., Dai, J. P., Dedovich, D., Deng, Z. Y., Denig, A., Destefanis, I. Denysenko M., Ding, W. M., Ding, Y., Dong, L. Y., Dong, M. Y., Du, S. X., Fang, J., Fang, S. S., Feldbauer, L. Fava F., Feng, C. Q., Ferroli, R. B., Fu, C. D., Fu, J. L., Gao, Y., Geng, C., Goetzen, K., Gong, W. X., Gradl, W., Greco, M., Gu, M. H., Gu, Y. T., Guan, Y. H., Guo, A. Q., Guo, L. B., Guo, Y. P., Han, Y. L., Harris, F. A., He, K. L., He, M., He, Z. Y., Held, T., Heng, Y. K., Hou, Z. L., Hu, H. M., Hu, J. F., Hu, T., Huang, G. M., Huang, G. S., Huang, J. S., Huang, X. T., Huang, Y. P., Hussain, T., Ji, C. S., Ji, Q., Ji, Q. P., Ji, X. B., Ji, X. L., Jiang, L. L., Jiang, X. S., Jiao, J. B., Jiao, Z., Jin, D. P., Jin, S., Jing, F. F., Kalantar-Nayestanaki, N., Kavatsyuk, M., Kornicer, M., Kuehn, W., Lai, W., Lange, J. S., Li, C. H., Li, Cheng, Li, Cui, Li, D. M., Li, F., Li, G., Li, H. B., Li, J. C., Li, K., Li, Lei, Li, Q. J., Li, S. L., Li, W. D., Li, W. G., Li, X. L., Li, X. N., Li, X. Q., Li, X. R., Li, Z. B., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, X. T., Liu, B. J., Liu, C. L., Liu, C. X., Liu, C. Y., Liu, F. H., Liu, Fang, Liu, Feng, Liu, H., Liu, H. H., Liu, H. M., Liu, H. W., Liu, J. P., Liu, K. Y., Liu, Kai, Liu, P. L., Liu, Q., Liu, S. B., Liu, X., Liu, Y. B., Liu, Z. A., Liu, Zhiqiang, Liu, Zhiqing, Loehner, H., Lu, G. R., Lu, H. J., Lu, J. G., Lu, Q. W., Lu, X. R., Lu, Y. P., Luo, C. L., Luo, M. X., Luo, T., Luo, X. L., Lv, M., Ma, C. L., Ma, F. C., Ma, H. L., Ma, Q. M., Ma, S., Ma, T., Ma, X. Y., Ma, Y., Maas, F. E., MaggioraA, M., Malik, Q. A., Mao, Y. J., Mao, Z. P., Messchendorp, J. G., Min, J., Min, T. J., Mitchell, R. E., Mo, X. H., Morales, C. Morales, Motzko, C., Muchnoi, N. Yu., Muramatsu, H., Nefedov, Y., Nicholson, C., Nikolaev, I. B., Ning, Z., Olsen, S. L., Ouyang, Q., PacettiB, S., Park, J. W., Pelizaeus, M., Peng, H. P., Peters, K., Ping, J. L., Ping, R. G., Poling, R., Prencipe, E., Qi, M., Qian, S., Qiao, C. F., Qin, X. S., Qin, Y., Qin, Z. H., Qiu, J. F., Rashid, K. H., Rong, G., Ruan, X. D., Sarantsev, A., Schaefer, B. D., Schulze, J., Shao, M., Shen, C. P., Shen, X. Y., Sheng, H. Y., Shepherd, M. R., Song, X. Y., Spruck, S. SpataroA B., Sun, D. H., Sun, G. X., Sun, J. F., Sun, S. S., Sun, Y. J., Sun, Y. Z., Sun, Z. J., Sun, Z. T., Tang, C. J., Tang, X., TapanC, I., Thorndike, E. H., Toth, D., Ullrich, M., Varner, G. S., Wang, B., Wang, B. Q., Wang, D., Wang, D. Y., Wang, K., Wang, L. L., Wang, L. S., Wang, M., Wang, P., Wang, P. L., Wang, Q., Wang, Q. J., Wang, S. G., Wang, X. L., Wang, Y. D., Wang, Y. F., Wang, Y. Q., Wang, Z., Wang, Z. G., Wang, Z. Y., Wei, D. H., Wei, J. B., Weidenkaff, P., Wen, Q. G., Wen, S. P., Werner, M., Wiedner, U., Wu, L. H., Wu, N., Wu, S. X., Wu, W., Wu, Z., Xia, L. G., Xiao, Z. J., Xie, Y. G., Xiu, Q. L., Xu, G. F., Xu, G. M., Xu, H., Xu, Q. J., Xu, X. P., Xu, Z. R., Xue, F., Xue, Z., Yan, L., Yan, W. B., Yan, Y. H., Yang, H. X., Yang, Y., Yang, Y. X., Ye, H., Ye, M., Ye, M. H., Yu, B. X., Yu, C. X., Yu, H. W., Yu, J. S., Yu, S. P., Yuan, C. Z., Yuan, Y., Zafar, A. A., Zallo, A., Zeng, Y., Zhang, B. X., Zhang, B. Y., Zhang, C., Zhang, C. C., Zhang, D. H., Zhang, H. H., Zhang, H. Y., Zhang, J. Q., Zhang, J. W., Zhang, J. Y., Zhang, J. Z., Zhang, S. H., Zhang, X. J., Zhang, X. Y., Zhang, Y., Zhang, Y. H., Zhang, Y. S., Zhang, Z. P., Zhang, Z. Y., Zhao, G., Zhao, H. S., Zhao, J. W., Zhao, K. X., Zhao, Lei, Zhao, Ling, Zhao, M. G., Zhao, Q., Zhao, Q. Z., Zhao, S. J., Zhao, T. C., Zhao, X. H., Zhao, Y. B., Zhao, Z. G., Zheng, A. Zhemchugov B., Zheng, J. P., Zheng, Y. H., Zhong, B., Zhong, J., Zhong, Z., Zhou, L., Zhou, X. K., Zhou, X. R., Zhu, C., Zhu, K., Zhu, K. J., Zhu, S. H., Zhu, X. L., Zhu, Y. C., Zhu, Y. M., Zhu, Y. S., Zhu, Z. A., Zhuang, J., Zou, B. S., and Zou, J. H.
- Subjects
High Energy Physics - Experiment - Abstract
We present a precision study of the $\psip\to\pi^0 J/\psi$ and $\eta J/\psi$ decay modes. The measurements are obtained using $106\times10^6$ $\psi'$ events accumulated with the BESIII detector at the BEPCII $\ee$ collider operating at a center-of-mass energy corresponding to the $\psip$ mass. We obtain $\mathcal{B}(\psip\to\pi^0 J/\psi)=(1.26\pm0.02{\rm (stat.)}\pm0.03{\rm (syst.)})\times 10^{-3}$ and $\mathcal{B}(\psip\to\eta J/\psi)=(33.75\pm0.17{\rm (stat.)}\pm0.86{\rm (syst.)})\times 10^{-3}$. The branching fraction ratio $R=\frac{\mathcal{B}(\psip\to\pi^0 J/\psi)}{\mathcal{B}(\psip\to\eta J/\psi)}$ is determined to be $(3.74\pm0.06 {\rm(stat.)}\pm0.04 {\rm(syst.)})\times 10^{-2}$. The precision of these measurements of $\mathcal{B}(\psip\to\pi^{0} J/\psi)$ and $R$ represent a significant improvement over previously published values., Comment: four figures, 12 pages
- Published
- 2012
- Full Text
- View/download PDF
99. Observation of $\eta_{c}$ decay into $\Sigma^{+}\bar{\Sigma}^{-}$ and $\Xi^{-}\bar{\Xi}^{+}$ final states
- Author
-
The BESIII Collaboration, Ablikim, M., Achasov, M. N., Albayrak, O., Ambrose, D. J., An, F. F., An, Q., Bai, J. Z., Ban, Y., Becker, J., Bennett, J. V., Bertani, M., Bian, J. M., Boger, E., Bondarenko, O., Boyko, I., Briere, R. A., Bytev, V., Cai, X., Cakir, O., Calcaterra, A., Cao, G. F., Cetin, S. A., Chang, J. F., Chelkov, G., Chen, G., Chen, H. S., Chen, J. C., Chen, M. L., Chen, S. J., Chen, X., Chen, Y. B., Cheng, H. P., Chu, Y. P., Coccetti, F., Cronin-Hennessy, D., Dai, H. L., Dai, J. P., Dedovich, D., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., Ding, W. M., Ding, Y., Dong, L. Y., Dong, M. Y., Du, S. X., Fang, J., Fang, S. S., Fava, L., Feldbauer, F., Feng, C. Q., Ferroli, R. B., Fu, C. D., Fu, J. L., Gao, Y., Geng, C., Goetzen, K., Gong, W. X., Gradl, W., Greco, M., Gu, M. H., Gu, Y. T., Guan, Y. H., Guo, A. Q., Guo, L. B., Guo, Y. P., Han, Y. L., Harris, F. A., He, K. L., He, M., He, Z. Y., Held, T., Heng, Y. K., Hou, Z. L., Hu, H. M., Hu, J. F., Hu, T., Huang, G. M., Huang, G. S., Huang, J. S., Huang, X. T., Huang, Y. P., Hussain, T., Ji, C. S., Ji, Q., Ji, Q. P., Ji, X. B., Ji, X. L., Jiang, L. L., Jiang, X. S., Jiao, J. B., Jiao, Z., Jin, D. P., Jin, S., Jing, F. F., Kalantar-Nayestanaki, N., Kavatsyuk, M., Kornicer, M., Kuehn, W., Lai, W., Lange, J. S., Li, C. H., Li, Cheng, Li, Cui, Li, D. M., Li, F., Li, G., Li, H. B., Li, J. C., Li, K., Li, Lei, Li, Q. J., Li, S. L., Li, W. D., Li, W. G., Li, X. L., Li, X. N., Li, X. Q., Li, X. R., Li, Z. B., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, X. T., Liu, B. J., Liu, C. L., Liu, C. X., Liu, C. Y., Liu, F. H., Liu, Fang, Liu, Feng, Liu, H., Liu, H. H., Liu, H. M., Liu, H. W., Liu, J. P., Liu, K. Y., Liu, Kai, Liu, P. L., Liu, Q., Liu, S. B., Liu, X., Liu, Y. B., Liu, Z. A., Liu, Zhiqiang, Liu, Zhiqing, Loehner, H., Lu, G. R., Lu, H. J., Lu, J. G., Lu, Q. W., Lu, X. R., Lu, Y. P., Luo, C. L., Luo, M. X., Luo, T., Luo, X. L., Lv, M., Ma, C. L., Ma, F. C., Ma, H. L., Ma, Q. M., Ma, S., Ma, T., Ma, X. Y., Ma, Y., Maas, F. E., Maggiora, M., Malik, Q. A., Mao, Y. J., Mao, Z. P., Messchendorp, J. G., Min, J., Min, T. J., Mitchell, R. E., Mo, X. H., Morales, C. Morales, Motzko, C., Muchnoi, N. Yu., Muramatsu, H., Nefedov, Y., Nicholson, C., Nikolaev, I. B., Ning, Z., Olsen, S. L., Ouyang, Q., Pacetti, S., Park, J. W., Pelizaeus, M., Peng, H. P., Peters, K., Ping, J. L., Ping, R. G., Poling, R., Prencipe, E., Qi, M., Qian, S., Qiao, C. F., Qin, X. S., Qin, Y., Qin, Z. H., Qiu, J. F., Rashid, K. H., Rong, G., Ruan, X. D., Sarantsev, A., Schaefer, B. D., Schulze, J., Shao, M., Shen, C. P., Shen, X. Y., Sheng, H. Y., Shepherd, M. R., Song, X. Y., Spataro, S., Spruck, B., Sun, D. H., Sun, G. X., Sun, J. F., Sun, S. S., Sun, Y. J., Sun, Y. Z., Sun, Z. J., Sun, Z. T., Tang, C. J., Tang, X., Tapan, I., Thorndike, E. H., Toth, D., Ullrich, M., Varner, G. S., Wang, B., Wang, B. Q., Wang, D., Wang, D. Y., Wang, K., Wang, L. L., Wang, L. S., Wang, M., Wang, P., Wang, P. L., Wang, Q., Wang, Q. J., Wang, S. G., Wang, X. L., Wang, Y. D., Wang, Y. F., Wang, Y. Q., Wang, Z., Wang, Z. G., Wang, Z. Y., Wei, D. H., Wei, J. B., Weidenkaff, P., Wen, Q. G., Wen, S. P., Werner, M., Wiedner, U., Wu, L. H., Wu, N., Wu, S. X., Wu, W., Wu, Z., Xia, L. G., Xiao, Z. J., Xie, Y. G., Xiu, Q. L., Xu, G. F., Xu, G. M., Xu, H., Xu, Q. J., Xu, X. P., Xu, Z. R., Xue, F., Xue, Z., Yan, L., Yan, W. B., Yan, Y. H., Yang, H. X., Yang, Y., Yang, Y. X., Ye, H., Ye, M., Ye, M. H., Yu, B. X., Yu, C. X., Yu, H. W., Yu, J. S., Yu, S. P., Yuan, C. Z., Yuan, Y., Zafar, A. A., Zallo, A., Zeng, Y., Zhang, B. X., Zhang, B. Y., Zhang, C., Zhang, C. C., Zhang, D. H., Zhang, H. H., Zhang, H. Y., Zhang, J. Q., Zhang, J. W., Zhang, J. Y., Zhang, J. Z., Zhang, S. H., Zhang, X. J., Zhang, X. Y., Zhang, Y., Zhang, Y. H., Zhang, Y. S., Zhang, Z. P., Zhang, Z. Y., Zhao, G., Zhao, H. S., Zhao, J. W., Zhao, K. X., Zhao, Lei, Zhao, Ling, Zhao, M. G., Zhao, Q., Zhao, Q. Z., Zhao, S. J., Zhao, T. C., Zhao, X. H., Zhao, Y. B., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, J. P., Zheng, Y. H., Zhong, B., Zhong, J., Zhong, Z., Zhou, L., Zhou, X. K., Zhou, X. R., Zhu, C., Zhu, K., Zhu, K. J., Zhu, S. H., Zhu, X. L., Zhu, Y. C., Zhu, Y. M., Zhu, Y. S., Zhu, Z. A., Zhuang, J., Zou, B. S., and Zou, J. H.
- Subjects
High Energy Physics - Experiment - Abstract
Using a data sample of $2.25\times10^{8}$ $J/\psi$ events collected with the BESIII detector, we present the first observation of the decays of $\eta_{c}$ mesons to $\Sigma^{+}\bar{\Sigma}^{-}$ and $\Xi^{-}\bar{\Xi}^{+}$. The branching fractions are measured to be $(2.11\pm0.28_{\rm stat.}\pm0.18_{\rm syst.}\pm0.50_{\rm PDG})\times10^{-3}$ and $(0.89\pm0.16_{\rm stat.}\pm0.08_{\rm syst.}\pm0.21_{\rm PDG})\times10^{-3}$ for $\eta_{c} \to \Sigma^{+}\bar{\Sigma}^{-}$ and $\Xi^{-}\bar{\Xi}^{+}$, respectively. These branching fractions provide important information on the helicity selection rule in charmonium-decay processes., Comment: 17 pages, 8 figures
- Published
- 2012
- Full Text
- View/download PDF
100. Study of $\psi(3686)\to\pi^0 h_c, h_c\to\gamma\eta_c$ via $\eta_c$ exclusive decays
- Author
-
The BESIII Collaboration, Ablikim, M., Achasov, M. N., Albayrak, O., Ambrose, D. J., An, F. F., An, Q., Bai, J. Z., Ban, Y., Becker, J., Bennett, J. V., Bertani, M., Bian, J. M., Boger, E., Bondarenko, O., Boyko, I., Briere, R. A., Bytev, V., Cai, X., Cakir, O., Calcaterra, A., Cao, G. F., Cetin, S. A., Chang, J. F., Chelkov, G., Chen, G., Chen, H. S., Chen, J. C., Chen, M. L., Chen, S. J., Chen, X., Chen, Y. B., Cheng, H. P., Chu, Y. P., Cronin-Hennessy, D., Dai, H. L., Dai, J. P., Dedovich, D., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., Ding, W. M., Ding, Y., Dong, L. Y., Dong, M. Y., Du, S. X., Fang, J., Fang, S. S., Fava, L., Feldbauer, F., Feng, C. Q., Ferroli, R. B., Fu, C. D., Fu, J. L., Gao, Y., Geng, C., Goetzen, K., Gong, W. X., Gradl, W., Greco, M., Gu, M. H., Gu, Y. T., Guan, Y. H., Guo, A. Q., Guo, L. B., Guo, Y. P., Han, Y. L., Harris, F. A., He, K. L., He, M., He, Z. Y., Held, T., Heng, Y. K., Hou, Z. L., Hu, H. M., Hu, T., Huang, G. M., Huang, G. S., Huang, J. S., Huang, X. T., Huang, Y. P., Hussain, T., Ji, C. S., Ji, Q., Ji, Q. P., Ji, X. B., Ji, X. L., Jiang, L. L., Jiang, X. S., Jiao, J. B., Jiao, Z., Jin, D. P., Jin, S., Jing, F. F., Kalantar-Nayestanaki, N., Kavatsyuk, M., Kuehn, W., Lai, W., Lange, J. S., Li, C. H., Li, Cheng, Li, Cui, Li, D. M., Li, F., Li, G., Li, H. B., Li, J. C., Li, K., Li, Lei, Li, Q. J., Li, S. L., Li, W. D., Li, W. G., Li, X. L., Li, X. N., Li, X. Q., Li, X. R., Li, Z. B., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, X. T., Liu, B. J., Liu, C. L., Liu, C. X., Liu, C. Y., Liu, F. H., Liu, Fang, Liu, Feng, Liu, H., Liu, H. H., Liu, H. M., Liu, H. W., Liu, J. P., Liu, K. Y., Liu, Kai, Liu, P. L., Liu, Q., Liu, S. B., Liu, X., Liu, Y. B., Liu, Z. A., Liu, Zhiqiang, Liu, Zhiqing, Loehner, H., Lu, G. R., Lu, H. J., Lu, J. G., Lu, Q. W., Lu, X. R., Lu, Y. P., Luo, C. L., Luo, M. X., Luo, T., Luo, X. L., Lv, M., Ma, C. L., Ma, F. C., Ma, H. L., Ma, Q. M., Ma, S., Ma, T., Ma, X. Y., Ma, Y., Maas, F. E., Maggiora, M., Malik, Q. A., Mao, Y. J., Mao, Z. P., Messchendorp, J. G., Min, J., Min, T. J., Mitchell, R. E., Mo, X. H., Morales, C. Morales, Motzko, C., Muchnoi, N. Yu., Muramatsu, H., Nefedov, Y., Nicholson, C., Nikolaev, I. B., Ning, Z., Olsen, S. L., Ouyang, Q., Pacetti, S., Park, J. W., Pelizaeus, M., Peng, H. P., Peters, K., Ping, J. L., Ping, R. G., Poling, R., Prencipe, E., Qi, M., Qian, S., Qiao, C. F., Qin, X. S., Qin, Y., Qin, Z. H., Qiu, J. F., Rashid, K. H., Rong, G., Ruan, X. D., Sarantsev, A., Schaefer, B. D., Schulze, J., Shao, M., Shen, C. P., Shen, X. Y., Sheng, H. Y., Shepherd, M. R., Song, X. Y., Spataro, S., Spruck, B., Sun, D. H., Sun, G. X., Sun, J. F., Sun, S. S., Sun, Y. J., Sun, Y. Z., Sun, Z. J., Sun, Z. T., Tang, C. J., Tang, X., Tapan, I., Thorndike, E. H., Toth, D., Ullrich, M., Varner, G. S., Wang, B., Wang, B. Q., Wang, D., Wang, D. Y., Wang, K., Wang, L. L., Wang, L. S., Wang, M., Wang, P., Wang, P. L., Wang, Q., Wang, Q. J., Wang, S. G., Wang, X. L., Wang, Y. D., Wang, Y. F., Wang, Y. Q., Wang, Z., Wang, Z. G., Wang, Z. Y., Wei, D. H., Wei, J. B., Weidenkaff, P., Wen, Q. G., Wen, S. P., Werner, M., Wiedner, U., Wu, L. H., Wu, N., Wu, S. X., Wu, W., Wu, Z., Xia, L. G., Xiao, Z. J., Xie, Y. G., Xiu, Q. L., Xu, G. F., Xu, G. M., Xu, H., Xu, Q. J., Xu, X. P., Xu, Z. R., Xue, F., Xue, Z., Yan, L., Yan, W. B., Yan, Y. H., Yang, H. X., Yang, Y., Yang, Y. X., Ye, H., Ye, M., Ye, M. H., Yu, B. X., Yu, C. X., Yu, H. W., Yu, J. S., Yu, S. P., Yuan, C. Z., Yuan, Y., Zafar, A. A., Zallo, A., Zeng, Y., Zhang, B. X., Zhang, B. Y., Zhang, C., Zhang, C. C., Zhang, D. H., Zhang, H. H., Zhang, H. Y., Zhang, J. Q., Zhang, J. W., Zhang, J. Y., Zhang, J. Z., Zhang, S. H., Zhang, X. J., Zhang, X. Y., Zhang, Y., Zhang, Y. H., Zhang, Y. S., Zhang, Z. P., Zhang, Z. Y., Zhao, G., Zhao, H. S., Zhao, J. W., Zhao, K. X., Zhao, Lei, Zhao, Ling, Zhao, M. G., Zhao, Q., Zhao, Q. Z., Zhao, S. J., Zhao, T. C., Zhao, X. H., Zhao, Y. B., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, J. P., Zheng, Y. H., Zhong, B., Zhong, J., Zhong, Z., Zhou, L., Zhou, X. K., Zhou, X. R., Zhu, C., Zhu, K., Zhu, K. J., Zhu, S. H., Zhu, X. L., Zhu, Y. C., Zhu, Y. M., Zhu, Y. S., Zhu, Z. A., Zhuang, J., Zou, B. S., and Zou, J. H.
- Subjects
High Energy Physics - Experiment - Abstract
The process $\psi(3686) \to \pi^0 h_c, h_c \to \gamma \eta_c$ has been studied with a data sample of $106 \pm 4$ million $\psi(3686)$ events collected with the BESIII detector at the BEPCII storage ring. The mass and width of the $P$-wave charmonium spin-singlet state $h_c(^1P_1)$ are determined by simultaneously fitting distributions of the $\pi^0$ recoil mass for 16 exclusive $\eta_c$ decay modes. The results, $M(\hc) = 3525.31 \pm 0.11 {\rm (stat.)} \pm 0.14 {\rm (syst.)}$\,MeV/$c^2$ and $\Gamma(\hc) = 0.70 \pm 0.28 \pm 0.22$\,MeV, are consistent with and more precise than previous measurements. We also determine the branching ratios for the 16 exclusive $\eta_c$ decay modes, five of which have not been measured previously. New measurements of the $\eta_c$ line-shape parameters in the $E1$ transition $h_c\to\gamma\eta_c$ are made by selecting candidates in the $h_c$ signal sample and simultaneously fitting the hadronic mass spectra for the 16 $\eta_c$ decay channels. The resulting $\eta_c$ mass and width values are $M(\eta_c) = 2984.49 \pm 1.16 \pm 0.52$\,MeV/$c^2$ and $\Gamma(\eta_c) = 36.4 \pm 3.2 \pm 1.7$\,MeV., Comment: 21 pages, 5 figures
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.